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Abstract (the text has to fit into the space below) 
TRPV6 is a calcium entry channel that is strongly expressed in breast adenocarcinoma 
tissue. In this PhD-study we further confirmed this observation by analysis of breast 
cancer tissues, which indicated that TRPV6 mRNA expression was upregulated 
compared to normal breast tissue. While TRPV6 is known to be expressed in the cancer 
tissue, its role as a calcium channel in breast carcinogenesis is poorly understood. 
Therefore, we investigated how TRPV6 affects viability, apoptosis, and calcium transport 
in breast cancer cell lines. TRPV6 expression can be regulated by estrogen, 
progesterone, 1,25-vitamin D, and tamoxifen (a selective estrogen receptor modulator that 
is widely used in breast cancer therapy) in T47D cells. Knockdown of TRPV6 in this cell 
model leads to a significant decrease of cell viability. Moreover, the effect of tamoxifen on 
cell viability was enhanced when TRPV6 expression was silenced with siRNA. 
Interestingly, tamoxifen reduced expression of TRPV6 in T47D cells and is able to inhibit 
its calcium transport activity (IC50=7.5 µM) in Xenopus oocytes. We examined the effect of 
tamoxifen on TRPV6 function and intracellular calcium homeostasis in MCF-7 breast 
cancer cells transiently transfected with EYFP-C1-TRPV6 in detail. TRPV6 activity was 
measured with fluorescence microscopy using Fura-2. Tamoxifen decreased the transport 
rates of calcium and barium in transfected cells by 50%. This inhibitory effect was not 
blocked by the estrogen receptor antagonist, ICI 182,720 and a similar inhibition effect 
was also observed in MDA-MB-231 estrogen receptor negative cells. The effect of 
tamoxifen was completely blocked by activation of protein kinase C. Inhibiting PKC with 
calphostin C decreased TRPV6 activity but did not alter the effect of tamoxifen. These 
findings illustrate how tamoxifen might be effective in estrogen receptor negative breast 
carcinomas and suggest that the mechanisms of tamoxifen and PKC inhibitors used in 
breast cancer therapy might involve TRPV6 mediated calcium entry. This PhD-study 
highlights a possible role of TRPV6 as a therapeutic target in breast cancer therapy.  
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ABBREVIATIONS 
 
VOCCs   voltage-operated calcium channel 
ROCCs   receptor-operated calcium channel 
SOCCs   store-operated calcium channel 
TRP    transient receptor potential 
PM    plasma membrane 
ER    estrogen receptor 
TRPC   transient receptor potential for canonical or classical 
TRPV   transient receptor potential for vanilloid 
TRPM   transient receptor potential for melastatin 
TRPP   transient receptor potential for polycystins 
PKD    polycystic kidney disease 
TRPA   transient receptor potential for ankyrin 
TRPML   transient receptor potential formucolipin 
TRPN   transient receptor potential for no mechano-receptor potential 
SNARE   soluble N-ethylmaleimide-sensitive-factor attachment receptor 
Src kinase  sarcoma kinase 
PI3K   phosphoinositide-3- kinase  
2-APB   2-aminoethoxydiphenylborate 
CNS    central nervous system 
PUFA   polyunsaturated fatty acid 
4α-PDD  4α-phorbol 12,13-didecanoate 
PACSIN  for PKC and CK2 substrate in neurons 
mRNA   messenger RNA 
DMEM   dimethylsulfoxide 
FBS    fetal bovine serum 
DMSO   dimethylsulfoxide 
EYFP    enhanced yellow fluorescence protein 
TG    thapsigargin 
PARP1   poly (ADP-ribose) polymerase-1 
PIP2   phosphatidylinositol biphosphate 
TMD   transmembrane domains 
PLC   phospholipase C 
PKC   proteinkinase C 
PTH   parathyroid hormone 
vitamin D3  1, 25 dihydroxy vitamin D3 
NFAT   nuclear factor of activated T-cells 
siRNA   small interfering RNA 
DCT   distal convoluted tubule 
CNT   connecting tubule 
VDR   vitamin D receptor 
HEK cells  human embryonic kidney 293 cells 
VDDR-I  vitamin D dependency rickets type I 
HER2   human epidermal growth factor receptor 2 
CaM   calmodulin 
GST pull-down assay glutathione S-transferase pull-down assay 
SERM   selective estrogen receptor modulators 
 7
CaR   Ca2+ sensing receptor 
WNK3   WNK lysine deficient protein kinase 3 
PTP1B  protein tyrosine phosphatase-1B 
S100A10  S100 calcium binding protein A10 
LNCaP   origin: lymph node carcinoma of the prostate  
PC-3   origin: prostate cancer 
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1. Introduction 
 
1.1 Calcium Entry Channels 
 
The channels that mediate calcium influx form the extracellular space into the cell 
can be grouped into four categories: (I) Voltage-operated calcium channels (VOCCs). 
These channels are mainly found in excitable cells and they act in response to 
membrane depolarization and can be regulated by second messengers, drugs and 
toxins (1;2). (II) Voltage-independent receptor-operated calcium channels (ROCCs) 
that function after stimulation of a membrane receptor. (III) Store-operated calcium 
channels (SOCCs) are activated by depletion of sarcoplasmatic reticulum and 
endoplasmatic reticulum calcium stores (3). (IV) Epithelial calcium entry channels 
that allow apical calcium entry in absorptive and secretory tissues (4). 
 
1.2 TRP channels 
 
Category (IV) and in part category (III) belong to the Transient Receptor Potential 
(TRP) superfamily. These channels can be activated by light, sound, chemical, 
temperature, touch stimuli or hyperpolarisation. They can also be receptor activated 
by e.g. PIP2, activated by specific ligands like capsaicin (5). The different activation 
mechanisms and the diversity of cation selectivity of members of the TRP family 
allow the detection of different types of changes in the close surrounding of the 
channels.  
 
All the TRP channels have a common structure that contains six transmembrane 
domains (TMD) with a pore region between TMD five and TMD six and an 
intracellularly localized amino- and carboxyl-terminus (Figure 1). Based on homology 
and structure, they can be divided into two groups.  
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Figure 1: The TRP superfamily. (a) Single members from each of the five group 1 subfamilies. (b) 
Single members from each of the two group 2 subfamilies. The following domains are shown: A, 
ankyrin repeats; cc, coiled-coil domain; protein kinase domain; TRP domain. Also shown are 
transmembrane segments (vertical rectangles) and the pore loop region (P) which allows the passage 
of cations (+++). (c) Composition of the TRP superfamily in worms, flies, mice, and humans. 1Human 
TRPC2 is a pseudogene and is not counted. 2TRPP1-like proteins are not counted (6). 
 
Group 1 includes the TRPV, TRPM, TRPA, TRPN, and TRPC subfamily. These 
subfamilies show the closest sequence homology to the Drosophila TRP channel 
that was first identified in 1989 (7). Amongst them the classical TRPC channels show 
the highest homology to Drosophila TRP. Interestingly, some members of the TRPM 
family are classified as chanzymes that possess a C-terminal enzyme domain (8). 
The TRPM channels also differ from the other subfamilies since they exhibit no 
ankyrin repeats in their structures. The members of the TRPA subfamily play a major 
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role in thermosensation (9-11). Not much information is available about TRPN 
channels, which are not expressed in mammals.  
A specific feature of the members of group 2 (TRPP and TRPML) is that they 
additionally contain a large extracellular loop between the first and second TMD. 
Both members were identified because their mutation causes human diseases. A 
mutation in TRPP causes autosomal dominant polycystic kidney disease and one in 
TRPML muculipidosis type IV(12-15). Other known TRP channel mutations are 
present in group 1. Mutations in TRPC6 can result in glumerulosclerosis and a 
mutation in TRPM6 leads to hypomagnesemia (16-19).  
 
1.3 TRPV channels 
1.3.1 TRPV1 
 
The TRPV channels were first identified through expression cloning. Application of 
this method resulted in the identification of TRPV1 (20) Subsequently, the other 
members of the TRPV family were identified:  
Capsaicin, the active component of chili peppers that produces a sensation of 
burning, was applied to identify the TRPV1 channel (21). This channel is weakly 
calcium selective and outwardly rectified (22). Other stimuli that can activate TRPV1 
are heat (≥43°C) enhanced by low pH (23), anandamide (24), camphor (25), piperine 
(26), and garlic (27). TRPV1 is expressed in distinct dorsal root ganglia neurons, 
where it reacts to environmental changes (28) and it plays an essential role in 
inflammatory thermal hyperalgesia (29). It is also involved in mechanically evoked 
purinergic signaling in the bladder, gastrointestinal motility, hearing modulation, and 
satiety (30-33). TRPV1-knockout mice show impaired nociception and pain 
sensation (34). It was demonstrated that TRPV1 can be potentiated by an activation 
of phospholipase C (PLC) with proanalgesic agents, a subsequent decrease in PIP2 
levels, and phosphorylation through protein kinase C (PKC) (35). Important for TRPV 
channel activity is also the insertion and retention of the channel in the plasma 
membrane. TRPV1 can interact with members of the SNARE-dependent exocytic 
pathway and lead to PKC-mediated translocation of TRPV1 to the plasma 
membrane (36). Insertion of TRPV1 in the plasma membrane can be also triggered 
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by proalgesic factors such as nerve growth factors. This mechanism functions via 
phosphorylation of the channel on a tyrosine residue by Src kinase (37).  
1.3.2 TRPV2, TRPV3 and TRPV4 
 
A similar activation mechanism through heat is known for TRPV2, TRPV3, and 
TRPV4. TRPV2 is weakly calcium selective and activated at high temperatures 
>52ºC (38), whereas TRPV3 and TRPV4 are already activated at warm 
temperatures around 33ºC (39). Its activity is increased by application of 2-
aminoethoxydiphenylborate (2-APB) (40). It was found that TRPV2 function can be 
up regulated by phosphoinositide-3-kinase (PI3K) activation (41) and cell swelling 
induced by hypotonicity (42). TRPV2 activity is regulated by insertion of the channel 
into the plasma membrane from internal vesicles, which can be stimulated by insulin-
like growth factor-I treatment shown in an in vitro system (43). Protein expression of 
TRPV2 was detected in the CNS (44), the myenteric plexus, and in the nodose 
ganglion (45). 
In cell culture models, PLC stimulation (46), application of PUFAs (47), 2-APB (48), 
menthol, and some spices (49) induced a weakly calcium selective cationic 
conductance over TRPV3 (50). After heat activation TRPV3 currents are strong 
outwardly rectified and display a sensitization following repeated activation (51). 
TRPV3 protein is widely expressed in humans (52), but only in the skin of mice (53), 
where it might function in keratinocytes. Interestingly, there is evidence for an 
interaction of TRPV3 with TRPV1 (54) and TRPV2 (55), but the functional 
consequences are so far unidentified.  
Moderate heat, hypotonic challenge, and 4α-PDD can activate the calcium 
permeable, constitutively active, and outwardly rectified channel TRPV4. An 
induction of TRPV4 by extracellular hypotonicity requires the interaction of TRPV4 
with aquaporin 5 (56). Another mechanism of TRPV4 activation works over 
cytochrome P450-dependent formation of epoxyeicosatrienoic acids. This 
mechanism is triggered by anandamide and arachidonic acid (57). TRPV4 is in 
contrast to TRPV1, TRPV2, and TRPV3 not activated by 2-APB (58). TRPV4 KO 
mice show hearing loss and an impaired pressure, temperature, and osmotic 
sensitivity (59-62). Surface expression of TRPV4 involves its interaction with 
PACSINs (63) and glycosylation in the pore loop (64).  
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1.3.3 TRPV5 and TRPV6 
 
Different to the other TRPV channels are TRPV5 and TRPV6 (5;65;66). TRPV5 was 
identified via expression cloning from rabbit kidney (67) and TRPV6 from rat 
duodenum by Hediger and colleagues (68). 
They cannot be activated by heat and they exhibit the highest Ca2+ selectivity 
(PCa:PNa > 100) of all mammalian TRP channels (66;69-71). In the absence of 
extracellular calcium they are also permeable to monovalent cations (72). TRPV5 is 
mainly expressed in the kidney and responsible for calcium reabsorption via 
epithelial cells (73). Around 65% of the filtered calcium is passively reabsorbed in the 
proximal tubule, while 20% is reabsorbed by claudin-16 over tight junctions via a 
paracellular pathway. The final reabsorption of calcium occurs in the distal 
convoluted tubule (DCT) and the connecting tubule (CT) in a highly regulated 
manner via TRPV5 to maintain an appropriate total body calcium homeostasis (74). 
TRPV5 has, beside the general TRP structure, six ankyrin repeats at the amino-
terminus that are important for protein-protein interactions (75). The insertion of 
TRPV5 into the plasma membrane regulates its activity (76). Hydrolysis of 
extracellular sugar residues between TMD1 and TMD2 at an evolutionary conserved 
asparagine (N358) by the β-glucuronidase Klotho promotes retention of the channel in 
the plasma membrane (77). There are also three potential PKC phosphorylation 
sites that might play a role in regulating channel activity (78-80). The active 
conformation of TRPV5 is an assembly into homo-tetramers (81;82). Characteristic 
for TRPV5, which is constitutively active at physiological membrane potentials, is its 
high calcium selectivity and strong inward rectification (83). TRPV5 KO mice show 
dramatically reduced active Ca2+-reabsoption in the DCT and CNT and waste six- to 
ten-fold more calcium than wild-type mice (84).  
Shortly after the discovery of TRPV5, another TRP channel was found that shares 
75% amino acid identity to TRPV5. In 1999, TRPV6 was identified by Hediger and 
colleagues from rat duodenum using expression cloning (85). 
1.4.1 Structure of TRPV6 
 
TRPV6 shares the basic structure of TRP channels, which consist of intracellularly 
localized NH2- and COOH-terminal tails flanking six TMDs with a pore-forming loop 
between TMD5 and TMD6. On the NH2-terminus of TRPV6 are 3-4 ankyrin repeats 
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depending on the prediction algorithm (86). TRPV6 has a tetrameric structure where 
four subunits surround a single pore and can assemble in homo- and hetero-
tetramers with TRPV5 (87). It was shown that the ankyrin repeat at position 116-191 
of the NH2-terminus is very important for functional subunit assembly (88). A 
structural model of the TRPV6 outer pore by Voets et al. displayed that a mutation of 
an aspartate residue at position 542 can alter the pore diameter and is important for 
calcium binding (89). TRPV5 and TRPV6 are side by side on the human 
chromosome 7q35, have only a 22kb distance between each other, and comprise 15 
exons (90). TRPV6 consists of 730 amino acids and its predicted molecular mass is 
around 83kDa (91). 
1.4.2 Expression and function of TRPV6  
 
TRPV6 protein was detected in the apical membrane of epithelial cells of the 
intestine. The most abundant expression is found in the duodenum, although 
staining could be detected in the colon as well. In the duodenal villi at the brush 
border membrane, mRNA and protein could be detected at the upper part of the 
villus on the luminal side (92). 
 
 
Figure 2. Mechanism of intestinal calcium absorption in the intestine and kidney (66). 
 
TRPV6 plays a major role in intestinal calcium absorption. In the epithelial cells, 
calcium gets bound to calbindin D9k, which transports it to the basolateral 
membrane. There, calcium crosses the membrane via the Ca2+-ATPase PMCA1b 
and the Na+/ Ca2+ exchanger and enters the blood (66) (Figure 2).  
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The organ that shows the highest expression level for TRPV6 is the human placenta, 
where levels 50-fold higher than in the duodenum can be measured (93). Using in 
situ hybridization, TRPV6 was found in trophoblasts and syncytiotrophoblasts (94). 
Recently, Suzuki et al., showed that it is involved in maternal-fetal calcium transport 
by comparison of TRPV6-knockout mice with wild-type mice (95). Protein signals 
were also detected at the secretory poles of mouse pancreatic acinar cells and at the 
inner surface of ductal epithelial cells in human mammary and sweat glands (96). 
Weber at al., could measure TRPV6 for the first time in the murine skin (97) and 
Lehen’kyi et al., found recently that TRPV6 is essential for Ca2+-induced 
differentiation of human keratinocytes (98). TRPV6 is also expressed in the mouse 
inner ear and in human leukemia cells, where its function has not completely clarified 
thus far (99;100). 
Studies of Bianco et al., with TRPV6 knockout mice demonstrated that TRPV6 is 
most likely to be the major calcium channel responsible for apical intestinal 
absorption (101). In the knockout mice the intestinal calcium absorption was 
drastically reduced, the animals weighed less, and were less fertile compared to 
wild-type mice. The blood levels of PTH and 1,25-vitamin D of the knockout mice 
were elevated, showing a secondary hyperparathyroidism caused by reduced 
calcium absorption. Consequently, these animals have a reduced bone density, 
which might be due to increased bone resorption or a possible role of TRPV6 in 
bone cells. 
 
 
TRPV6 has special transport characteristics that are different to other calcium 
channels. One of them is that it is almost completely inwardly rectified (102). The 
other major characteristic of TRPV6 is its high calcium selectivity; permeation of Na+ 
versus Ca2+ is 1:100. The permeability of other divalent ions decreases from: Ca2+ > 
Ba2+ > Sr2+ > Mn2+ (103) (Figure 3).  
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Figure 3: Relative permeability in CaT1-expressing CHO-K1 cells (to Na+) of Cs+ (0.6), Ca2+ (130), 
Ba2+ (7.5), Sr2+ (5.1) and Mn2+ (2.4) through CaT1 channels (n=8 for each) (Yue et al., 2001 Nature) 
 
The Km-value for Ca2+ is 0.44mM. Known nonspecific blockers of TRPV6 are  
ruthenium red, Gd3+, and La3+ (104). Another nonspecific inhibitor of Ca2+/cation 
channels in non-excitable cells is econazole (105). Schwarz et al., found 2006 in 
calcium imaging experiments with HEK cells transfected with TRPV6 that 600nM 
econazole reduces [Ca2+]i (106). An nonspecific activator of TRPV6 is 2-APB, which 
could increase TRPV6 mediated currents with a concentration of 50µM (107). Until 
now, no specific inhibitors or activators are known. 
 
1.4.2 Regulation of TRPV6 
 
1. Regulation of channel abundance 
 
Vitamin D3 
Many studies demonstrated that vitamin D3 is very important for the regulation of 
TRPV6. First, TRPV6 promotor regions were identified that exhibit potential vitamin 
D3-response elements (108). Then, vitamin D3 application could enhance TRPV6 
mRNA expression in in vitro models with Caco-2 intestinal cell lines (109;110). In 
vivo a dose of vitamin D3 increased duodenal TRPV6 mRNA levels in mice (111). 
Another study showed the time dependency of this response, which takes place 3-6 
hours after stimulation (112). Studies with vitamin D3-receptor knockout mice 
revealed that these mice have significantly down regulated duodenal TRPV6 mRNA 
levels (113).  
 
Dietary calcium 
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Dietary calcium can also regulate TRPV6 expression. To study this, VDR-knockout 
mice and 1α-hydroxylase knockout mice were used because in wild-type mice the 
vitamin D levels would be affected as well and single effects could be distinguished. 
High dietary calcium intake restored the reduced expression level of intestinal 
TRPV6 in 1α-hydroxlase knockout mice and led to a normalization of the calcium 
level in the plasma (114). In a similar way, dietary calcium up regulated the 
decreased level of duodenal TRPV6 mRNA expression in vitamin D3 receptor 
knockout mice (115). Interestingly, the CaR (calcium sensing receptor) does not 
stimulate TRPV6 activity, in contrast to findings obtained with TRPV5 (116). 
 
Short chain fatty acids 
Fukushima et al., found recently that short-chain fatty acids induce TRPV6 
expression in rats and Caco-2 cells (117). 
 
Parathyroid hormone  
Parathyroid hormone (PTH) is secreted when the extracellular calcium level 
decreases. It acts on calcium reabsoption in the kidney and on calcium resorption 
from the bone to keep up the extracellular Ca2+ concentration. PTH also stimulates 1 
alpha-hydroxylase that is necessary for vitamin D3 synthesis. Therefore, PTH plays 
at least an indirect role in TRPV6 regulation.  
 
Oestrogens and androgens  
Similar to vitamin D3, an estrogen-responsive element was found in the promoter 
sequence of TRPV6 (118). An in vivo study showed that in ovariectomized rats and 
1α-hydroxylase knockout mice administration of 17β-estradiol led to an up regulation 
of duodenal TRPV6 mRNA and a normalization of plasma calcium (119). Another 
study demonstrated that in ER-knockout mice duodenal TRPV6 mRNA expression is 
lower than in wild-type mice and that it can be increased by estrogen treatment (120). 
TRPV6 regulation by androgens was shown first in a study of Peng et al., in prostate 
adenocarcinoma cell lines. The TRPV6 mRNA level was decreased by androgen 
and induced by an androgen receptor antagonist in LNCaP prostate cancer cells 
(121). Recent results of Lehen’kyi et al., suggest also, that TRPV6 expression in 
LNCaP cells is regulated by the androgen receptor (122).  
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2. Modulation of channel activity 
 
The channel activity of TRPV6 can be modulated first by the intracellular calcium 
concentration. If the intracellular calcium level increases, a rapid inactivation of 
TRPV6 occurs (123). This rapid inactivation by transported calcium gets mediated 
over an activation of PLC and a subsequent depletion of PIP2 (124). Secondly, the 
extracellular pH likely plays a role in activity modulation of TRPV6, because it was 
shown to be important for the calcium uptake through TRPV5 in Xenopus oocytes 
(125). The third factor was found by Nilius et al., when they demonstrated that influx 
of calcium and the intracellular calcium concentration induced feedback inhibition of 
the channel that is controlled by the intracellular calcium concentration in a micro 
domain close to the channel (126). Crucial for this process is a tyrosine T702 in the 
calmodulin binding site. Niemeyer et al., demonstrated that the phosphorylation of 
this tyrosine by PKC prevents calmodulin binding to the channel (127). Another 
group showed that inhibition of tyrosine phosphatase PTP1B increases TRPV6 
activity (128) (Figure 4). WNK3 is a member of the With No Lysine (K) family of 
serine/threonine kinases. By co-expressing WNK3 and TRPV6 in Xenopus oocytes, 
it was found that WNK3 enhanced Ca2+-influx and Na+-current mediated by TRPV6 
(129). 
 
N-terminal C-terminal
358
161-162
1 328
702
725578
Y
Y
Ankyrin repeat
Interaction with S100A10
Calmodulin binding site
PTP1B site
Glycosylsation site
PKC phosphorylation site
 
Figure 4. Structure of TRPV6 with special sites for activity modulation 
 
3. Regulation through trafficking  
 
TRPV6 expression at the cell surface is important for Ca2+ transport. As already 
noted, Klotho can hydrolyze extracellular sugar residues of TRPV5 resulting in cell 
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surface trapped TRPV5 (130). Lu et al., found that klotho and β-glucuronidase 
treatment also increases the activity of TRPV6 (131). 
 
4. Regulation by associated proteins 
 
S100A10/Annexin 2 
S100A10 was found to be an auxiliarly protein of TRPV6 using the yeast two-hybrid 
system (132). It is predominatly complexed with annexin 2 that binds to actin to 
interact with the membrane-cytoskeleton (133). Van de Graf et al., showed that 
S100A10, annexin 2, and TRPV6 are co-expressed in the small intestine (134). The 
important motive for the association of S100A10 with TRPV6 is the five amino acid 
containing, highly conserved, sequence VATTV at the carboxy-terminus of the 
channel. Regarding the function of annexins, the S100A10/Annexin 2 complex may 
regulate the translocation of the TRPV6 channel into the plasma membrane.  
 
Calmodulin 
Calmodulin (CaM) binds to the carboxy-terminus of human TRPV6 in a calcium-
dependent manner (135). When the calmodulin-binding site was removed from the 
carboxy-terminus of TRPV6, the channel had a significantly reduced slow-
inactivation (136). Another piece of evidence was that HEK cells heterologously co-
expressing calcium-insensitive CaM mutants with TRPV6 exhibited a significantly 
diminished calcium current (137).  
 
Rab11a 
Van de Graaf detected recently that Rab11a, a small GTPase important for 
trafficking, is associated with TRPV6 (138). TRPV6 co-localizes with Rab11a in the 
kidney in vesicular structures underlying the plasma membrane. The interaction was 
shown with a GST-pulldown assay and co-immunoprecipitation (139) and might 
indicate that Rab11a is important for TRPV6 trafficking to the membrane. 
1.4.3 Diseases associated with the dysfunction of TRPV6 
Vitamin D-deficiency rickets 
Vitamin D-deficiency rickets type I (VDDR-I) is characterized by very low levels of 
vitamin D3 in the plasma that cause hypocalcemia, richets, osteomalacia, growth 
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retardation, and failure to thrive. The reason for the low vitamin D3 levels is a 
mutation in the 1alpha-hydroxylase gene (140). 1alpha-hydroxylase knockout mice 
exhibit lower levels of TRPV6 mRNA expression in the intestine than wild-type mice 
(141). It is very likely that channel abundance leads to impaired renal and intestinal 
calcium absorption and consequently to hypocalcemia in VDDR-I. 
 
Hypercalciuria and kidney stone diseases 
One characteristic of TRPV6 knockout mice is calciuria with bone abnormalities 
similar to clinical hypercalciuria that might be possibly connected to idiopathic 
hypercalciuria. Another hypothesis is that urine calcium levels correlate with TRPV6 
gene mutations or polymorphisms. It is possible that hypercalciuria is one risk factor 
for kidney stone disease (142). It was also demonstrated that silencing mutations of 
TRPV5 and TRPV6 can hypothetically lead to primary renal as well as absorptive 
idiopathic hypercalciuria (143). Suzuki et al, found recently that the ancestral gain of 
function haplotype consisting of three non-synonymous polymorphisms in TRPV6 is 
important in calcium stone formation in hypercalciuria (144). 
 
Osteoporosis 
Estrogen deficiency after menopause results in a negative calcium balance that can 
induce osteoporosis (145). As mentioned before, estrogen regulates TRPV6 
expression and TRPV6-knockout mice show certain symptoms of osteoporosis like 
reduced bone density (146). Therefore, there might be a linkage of TRPV6 and 
osteoporosis. 
 
Cancer 
Recent studies indicate that TRPV6 plays a role in certain cancers of epithelial origin. 
Schwarz et al., demonstrated 2006 that the heterologous expression of TRPV6 in 
HEK cells leads to increased cell proliferation (147). It was also found that cancer 
cell lines express higher amounts of TRPV6 than normal cells e.g. LNCaP and PC-3 
prostate cancer cells, SW480 colorectal cancer cells, and K-562 chronic 
myelogenous leukaemia cell lines (148). Furthermore, Zhuang and colleagues 
detected that TRPV6 is higher expressed in tumor tissue compared to normal tissue 
of prostate, breast, colon, thyroid, and ovary (149) (Figure 5). 
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Figure 5. Immunohistochemical staining of CaT1 in human normal and tumor tissue.  
A. Positive staining of the epithelial ductal cells in the normal human mammary gland 
A1. and A2. Staining of mammary adenocarcinoma demonstrated a stronger positive reaction than its 
normal counterparts. Magnified views of expression patterns of human TRPV6 in A1 tumor tissues are 
shown in A2. (Original magnifications: A, A1,x200; A2,x400) (185). 
 
Most studies published so far concentrate on TRPV6 in prostate cancer. As 
mentioned before, there is higher expression in cancer tissue compared to normal 
tissue (150). The grade of TRPV6 expression in prostate cancer correlates with the 
Gleason grade (151). The mechanistic details of the role of TRPV6 in prostate 
carcinogenesis were investigated by Lehen’kyi et al., 2007. They showed that knock-
down of TRPV6 via siRNA led to decreased proliferation in LNCaP prostate cancer 
cells. Furthermore, they demonstrated that the calcium uptake in LNCaP cells is 
mediated by TRPV6 via a subsequent activation of nuclear factor of activated T-cell 
transcription factor (NFAT). They concluded that the up regulation of TRPV6 
expression in prostate cancer serves as a mechanism to increase proliferation rate, 
cell survival, and apoptosis resistance (152). These findings might indicate that 
TRPV6 expression could be used as a marker of the clinical outcome of prostate 
cancer (153-155). Other known TRP channels that are highly expressed in cancer 
cells are TRPM8 and TRPM1. Their protein expression is changed from normal to 
tumorigenic stage. The TRPC1, TRPC6, TRPM5, and TRPV1 are also increased in 
cancer tissues (156-158). Certainly, some of the mentioned channels might be 
diagnostic markers and they might have also potential as drug targets.  
 
1.5 Pathophysiology and therapeutic perspectives of 
breast carcinomas 
In 2006, breast cancer had the highest incidence rate of all cancers in Europe. It was 
ranked third among all cancer deaths (159). Stella Kyriakides, the president of 
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Europa Donna, the European Breast Cancer Coalition stated that: “Within the 
European Union, every 2.5 minutes a woman is diagnosed with breast cancer. Every 
7.5 minutes a woman dies from the disease” (160). For the development of 
additional therapies and new drugs, a better understanding of the physiology and 
pathophysiology of mammary gland is indispensable.  
 
Breast cancer treatment 
For the treatment of breast cancer four types of standard therapies are used. The 
first option for most patients with breast cancer is to have surgery to remove the 
tumor.  Secondly, there is radiation therapy that applies high-energy x-rays to kill 
cancer cells. A third therapy option is the chemotherapy that uses drugs to stop the 
growth of cancer cells by killing them or stopping them from dividing. The forth 
treatment possibility is hormone therapy, which removes hormones or blocks their 
action and stops cancer cell proliferation. These therapies are often applied in 
combinations. There are also new types of treatments being tested in clinical trials: 
one is the sentinel lymph node biopsy followed by surgery. Another approach is to 
use high-dose chemotherapy with stem cell transplant that should replace blood-
forming cells destroyed from the cancer treatment. The application of monoclonal 
antibodies as adjuvant therapy is also being investigated. The treatment is to 
administrate antibodies that can identify substances that are important for cancer 
cells and stop their growth. Trastuzumab (Herceptin) is a monoclonal antibody that 
blocks the effects of the growth factor protein HER2, which transmits growth signals 
to breast cancer cells. About one fourth of patients with breast cancer have tumors 
that may be treated with trastuzumab combined with chemotherapy. The 
administration of tyrosine kinase inhibitors might be also promising. They inhibit 
signals that the tumor needs to grow. Lapatinib is a tyrosine kinase inhibitor that 
blocks the impact of HER2 protein and other proteins inside tumor cells. It may be 
used to treat patients with HER2-positive breast cancer that has progressed 
following treatment with trastuzumab (161). 
Hormone therapy  
Exogenous estrogens and anti-estrogens are used for hormone-replacement therapy 
and as anti-cancer agents (162). There are three classes: the agonists, the mixed 
agonist-antagonists, and pure antagonists. The mixed agonist-antagonists are also 
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called selective estrogen receptor modulators (SERM). They exhibit a tissue specific 
activity (163). SERMs bind to the ER and change the biologic activity of the receptor 
(164). After discovery of the linkage between estrogen and breast cancer, the use of 
anti-estrogens as breast cancer drugs started. The first anti-estrogen, tamoxifen, 
was developed to inhibit the estrogen function. But tamoxifen is not a pure 
antagonist, it belongs to the SERMs because it works as antagonist in breast cancer 
cells, but functions as agonist in some other tissues like the liver. Tamoxifen is the 
standard hormonal therapy for breast cancer.  
 
Tamoxifen 
 
Tamoxifen is a lipophilic prodrug that can be easily absorbed in the intestine. In the 
blood, it is to 98% bound to albumin. In the gastrointestinal tract and in the liver it 
gets highly metabolized into the less active form N-desmethyl-tamoxifen and the two 
most active forms, 4-hydroxy-tamoxifen and endoxifen (165). The hydroxylated 
metabolites result from first pass metabolism in the liver and enter the blood stream 
over entero-hepatic circulation (166). 4-Hydoxy-tamoxifen and endoxifen have the 
same affinity for the ER as estrogen (167). 4-Hydroxy-tamoxifen possesses a higher 
ER-binding affinity than tamoxifen (168). Both metabolites can induce apoptotic cell 
death in ER-positive MCF-7 and ER-negative MDA-MB-231 and BT-20 breast 
cancer cells at micromolar concentrations (169). Tamoxifen binds to the two isoforms 
of the estrogen receptor ERα and ERβ with the same affinity (170). The tissue 
distribution and function of ERα and ERβ is variable, e.g. ERβ has an anti-
proliferative effect in many tissues and ERα is more proliferative (171). But the 
interaction of SERMs with the ER is very complex and dynamic and until now not 
fully understood. It is known that tamoxifen can affect the intracellular Ca2+ 
homeostasis in cells. For example, tamoxifen inhibits voltage-gated Ca2+ current (L- 
and T-type) and contractility in vascular smooth muscle cells in rats (172). The effect 
of tamoxifen is concentration dependent. At nanomolar concentrations tamoxifen 
leads to growth arrest, whereas at µM concentrations cell death is induced in cell 
cultures. The effects at nM concentrations were largely reversible by addition of 
estrogen, but those at µM concentrations were not (173). Many clinical studies 
showed that steady state concentrations of tamoxifen can be up to 1µM and mean 
intra-tumor concentration are even higher, about 4µM (174). In ER-negative tumors, 
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the therapeutic efficacy of tamoxifen has been obtained at doses 4- to 8- fold above 
those used for ER-inhibition. The anti-tumor effect of tamoxifen is thus believed to be 
a combination of genomic (ER-mediated) and non-genomic (non-ER-mediated or 
other signaling pathways) mechanisms. The signaling proteins in the non-ER-
mediated pathways include PKC, TGF-β, calmodulin, c-myc, ceramide, and MAP 
kinases (175). 
 
1.6 Role of calcium in cancer biology 
 
Calcium is important for many cellular processes, including the ones that are crucial 
for tumorigenesis, such as proliferation and apoptosis. Necessarily involved are 
calcium channels, pumps and exchangers, that are responsible for the fine tuning of 
the calcium homeostasis. The intracellular free calcium concentration is very 
important for proliferation and apoptosis and can be influenced by the calcium 
transport proteins. There is evidence that specific pumps or channels are up or down 
regulated in certain cancer types (176). One example for an up regulation is the 
increased expression of TRPM8 in prostate cancer (177;178). In contrast, SERCA3 
is down regulated in tissue samples of colon cancer patients (179).  
The extracellular free calcium is maintained at approximately 1.2mM, whereas the 
cytosolic calcium is approximately 100nM and can reach values of 1µM (180).  
Therefore, changes in free calcium concentration can be very potent and play a role 
in many processes in tumorigenesis. One of them is cellular motility. Another one is 
angiogenesis, where calcium is a key regulator of signaling pathways (181;182). In 
DNA damage response, calcium is important for genomic stability and cell survival, 
e.g. it can influence PARP1 activity (183). Transcription can be regulated directly via 
calcium oscillations that affect for example NFAT (nuclear factor of activated T-cells) 
(184). Interestingly, telomerase, that stabilizes the telomers, can inhibit the calcium 
effector S100A8 (185). Calcium signaling is also implicated in differentiation of 
cancer cells via the calcium sensing receptor (186). Excessive calcium accumulation 
in the mitochondria is one major characteristic for apoptosis and necrosis and is 
followed by mitochondrial membrane permeabilization (187). Finally, calcium is a key 
regulator of the cell cycle. It can increase proliferation by regulating the activity of ras 
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(188). Even direct modulation of cell-cycle is possible by calcium. It can activate 
transcription of genes important for Go-G1 transition and for the phosphorylation of 
retinoblastoma protein in late G1 (189) . 
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2. Hypothesis and Aim 
 
 
There is almost no information available about the calcium entry mechanism and 
regulation of the intracellular calcium in breast cancer cells. Studies performed thus 
far have focused on the role of TRPV6 in prostate cancer. Therefore, I investigated 
how TRPV6 affects proliferation, apoptosis, and calcium transport in breast cancer 
cell lines. Additionally, the hormonal effects of estradiol, progesterone, and 1,25-
vitamin D on TRPV6 expression were determined in T47D breast cancer cells. The 
apparent importance of calcium to breast tumor survival may lead to a therapeutic 
approach particularly apt for the treatment of breast tumors that are independent of 
estrogen and progesterone. These late stage tumors are highly metastatic and lethal 
and there is currently no effective treatment strategy. Understanding the relationship 
between calcium uptake induced through TRPV6 and the progression of breast 
tumor types might unveil TRPV6 as a novel target for anti-cancer drug development. 
The second aim of my studies is to investigate the effect of the most common breast 
cancer treatment drug, tamoxifen, on TRPV6 mediated calcium uptake in breast 
cancer cells and to find the mechanism of regulation and the subsequent implication 
of this for intracellular calcium homeostasis. Tamoxifen at lower dose induces a 
cytostatic, anti-proliferative effect via ER (estrogen receptors). However, at higher 
dose it is cytotoxic which is not ER-dependent, but involving alteration of intracellular 
calcium homeostasis. This latter effect is probably responsible for the side effects 
(thrombosis=altering platelet functions) and for its effectiveness in ER-negative 
breast cancer cells. But the exact mechanism of how tamoxifen acts in cancer cells 
is not clarified thus far. Since the calcium channel TRPV6 shows increased 
expression in breast cancer, I hypothesized that it is also involved in tamoxifen 
mediated effects. Our findings might help clarify an additional possible mechanism of 
how tamoxifen may function in breast cancer therapy. 
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3. Results 
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Abstract 
 
TRPV6 is a calcium entry channel that is strongly expressed in breast 
adenocarcinoma tissue.  In this study we further confirmed this observation by 
analysis of breast cancer tissues, which indicated that TRPV6 mRNA expression 
was upregulated between 2- and 15-fold compared to the average in normal breast 
tissue.  While TRPV6 is known to be expressed in the cancer tissue, its role as a 
calcium channel in breast carcinogenesis is poorly understood.  Therefore, we 
investigated how TRPV6 affects the viability, apoptosis, and calcium transport in the 
breast cancer cell line T47D.  Hormones can also affect the tumor development; 
hence we determined the effects of estradiol, progesterone, and 1,25-vitamin D on 
TRPV6 transcription.  Interestingly, the estrogen receptor antagonist tamoxifen 
reduced expression of TRPV6 and is able to inhibit its calcium transport activity 
(IC50=7.5 µM).  The in vitro model demonstrated that TRPV6 can be regulated by 
estrogen, progesterone, tamoxifen, and 1,25-vitamin D and has a large influence on 
breast cancer cell proliferation.  Moreover, the effect of tamoxifen on cell viability was 
enhanced when TRPV6 expression was silenced with siRNA.  TRPV6 may be a 
novel target for the development of calcium channel inhibitors to treat breast 
adenocarcinoma expressing TRPV6.  
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Introduction 
 
Ionized calcium (Ca2+) is a central signaling ion that is critical for controlling growth, 
proliferation, and survival of normal and malignant cells.  In cellular processes, 
calcium is a key modulator of numerous enzymes located in the cytosol, organelles, 
and nucleus. Ca2+ cannot be degraded like other second messenger signals. 
Therefore, the intracellular calcium levels are tightly regulated on multiple levels by 
plasma membrane ion channels, ion exchangers and pumps, as well as by the 
release of calcium from the endoplasmic reticulum and nuclear envelope (1, 2).   
 
One such plasma membrane channel is the TRPV6 calcium entry channel.  TRPV6 
is a Ca2+ permeable ion channel that was identified using expression cloning by 
Hediger and colleagues in 1999 (3). TRPV6 plays a central role in total body calcium 
homeostasis and its regulation directly affects intestinal calcium absorption, renal 
calcium excretion, and bone metabolism (4). TRPV6 appears to play a major role in 
facilitating the entry of Ca2+ into absorptive epithelial cells.  This is evident in TRPV6 
knockout (KO) mice, which exhibit defective intestinal Ca2+ absorption, increased 
urinary Ca2+ excretion, and decreased bone mineral density.  Regulation of TRPV6 is 
controlled by 1,25-vitamin D, estrogen, and dihydrotestosterone (5-7).  
 
While TRPV6 functions to maintain normal calcium homeostatsis, it also appears to 
play a role in tumor development and progression.  TRPV6 was observed to be 
upregulated in tissue samples originating from prostate, breast, thyroid, colon, ovary, 
and pancreatic tumors (8).  The channel has been localized to the apical membrane 
where it delivers calcium into the cells.  Furthermore, it has been shown that TRPV6 
is most strongly expressed in advanced stages of prostate cancer, while there is little 
to no expression evident in healthy tissue and benign prostate hyperplasia (7, 9).  
The transcript levels in both studies correlated positively with tumor progression and 
aggressiveness as indicated by the pathological stage and Gleason scores of the 
prostate tumors.  Endogenous store operated channels play important roles in the 
apoptosis of LNCaP prostate cancer cells (10, 11).  Numerous studies have linked 
enhanced endoplasmic reticulum (ER) Ca2+ accumulation to proliferation and/or 
apoptosis in prostate cancer (12-14).  A study by Schwarz et al., (2006) 
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demonstrated that TRPV6 clearly increases the rate of Ca2+ dependent cell 
proliferation in HEK cells (15). 
 
In mammary adenocarcinoma tissue, immunohistological analysis showed a clear 
enhancement in TRPV6 expression over normal tissue, suggesting it may play some 
role in the tumor development (8). Data from epidemiological studies suggest that 
higher intake of dietary calcium, which lowers 1,25-vitamin D levels in the blood, 
reduces the breast cancer risk in premenopausal women (16, 17).  Calcium also 
appears important to breast cancer progression, since bone metastases occur in up 
to 70% of patients with advanced breast cancer (18).  The metastatic cells at the 
bone are thus exposed to increased levels of free extracellular Ca2+ released from 
the mineralized bone matrix.  
The most common hormonal treatment for hormone receptor positive breast 
adenocarcinoma is the selective estrogen receptor modulator tamoxifen.  It blocks 
estrogens from signaling through the estrogen receptor (ER) and reduces the growth 
signals to the cells.  The activity of tamoxifen can be observed best in breast tumors 
that express ER and/or progesterone receptor (PR). The highest response rates are 
observed in tumors expressing both ER and PR (70%), with lower response rates in 
ER negative/PR positive tumors (45%), and ER positive/PR negative tumors (34%) 
(19, 20).  The lowest tamoxifen response rates are found in ER negative/PR 
negative tumors (<10%).  However, a portion of the supposed non-responders may 
actually be attributable to false negative assay data (21, 22).  
  
Little is known about the calcium entry mechanisms by which intracellular calcium is 
regulated in breast cancer cells. Therefore, in this study we investigated how TRPV6 
affects proliferation, apoptosis, and calcium transport in the breast cancer cell line 
T47D.  Additionally, the hormonal effects of estradiol, progesterone, and 1,25-vitamin 
D on TRPV6 expression were determined in the breast cancer cells.  The apparent 
importance of calcium to breast tumor survival may lead to a therapeutic approach 
particularly apt for the treatment of breast tumors that are independent of estrogen 
and progesterone. These late stage tumors are highly metastatic and lethal and 
there is currently no effective treatment strategy. Understanding the relationship 
between calcium uptake induced through TRPV6 and the progression of breast 
tumor types might unveil TRPV6 as a novel target for anti-cancer drug development. 
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Materials and methods 
 
Materials 
 
T47D cells were obtained from NIH Culture Collection.  Plastic 6-well culture dishes, 
96-well culture dishes, and T75 cultivation flasks were obtained from BD Falcon.  
RPMI-1640 cell culture medium, fetal bovine serum (FBS), trypsin, and 
penicillin/streptomycin were from Gibco.  Trizol reagent for RNA isolation was 
purchased from Invitrogen.  TaqMan Universal Master Mix for real time PCR was 
from Applied Biosystems.  siRNAs and HiPerFect transfection reagent were obtained 
from Qiagen. 1α,25-dihydroxyvitamin D3, β-estradiol, and progesterone were 
purchased from Sigma. Tamoxifen was obtained from Acros Organics.  Human 
Breast Cancer Rapid-Scan Gene cDNA Panel was purchased from Origene. 
 
Cell culture 
 
A human breast cancer cell line T47D was used in this study.  Tumor cells were 
grown in T75 culture flasks in RPMI medium supplemented with 10% FBS and 
antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) in a humidified 
atmosphere with 5% CO2.  Cells used in these studies were between passages 30 to 
40.  The cells were split twice a week. 
 
siRNA treatment 
 
For TRPV6 knockdown the following siRNAs were used:  
siRNA1 (target sequence): CTG CAT GTC AGA GCA CTT TAA 
siRNA2 (target sequence): AAC CTG CTG CAG CAG AAG AGG 
siRNA control: AAT CAT CTA AGC TGG CTT TGC 
The cells were seeded in 2 ml of culture medium at 400,000 cells per well in 6-well 
plates.  After 24 h, siRNA was diluted in phenol red free medium without FBS to give 
a final siRNA concentration of 5 nM (20 µM stock). Then, HiPerFect was added 
according to the manufacturer’s protocol and the mixture was incubated for 10 min at 
room temperature and added drop-wise onto cells.  Cells were incubated with 
siRNAs for 72 h before isolating RNA using the Trizol RNA isolation method 
according to manufacturer’s protocol. 
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Hormonal treatments  
 
For hormone treatment, T47D cells were seeded at 400,000 cells per well in 6-well 
dishes and grown for 48 h. Cells were serum-starved for 24 h prior to treatment. 
Then, cells were treated in the above mentioned culture medium without FBS for the 
duration of the studies.  After pilot studies to determine appropriate concentrations, 
100 nM 1,25-dihydroxyvitamin D (100 µM stock), 10 nM estradiol (10 µM stock), 100 
nM progesterone (100 µM stock), and 1 µM tamoxifen (1 mM stock) were all 
dissolved in ethanol and applied to the cells, along with ethanol only controls, for 24 
to 72 h.  Dose response studies during a 24 h treatment time were performed with 
estradiol and 1,25-dihydroxyvitamin D. Total RNA was harvested after 24, 48, and 72 
h of treatment.  Three independent experiments were performed with every 
treatment in triplicate. TRPV6 mRNA expression was determined by real time PCR.  
 
Real time PCR 
 
cDNA was prepared for every sample by reverse transcription of total RNA using 
TaqMan Reverse Transcription Reagents (Applied Biosystems) according to the 
manufacturer’s manual.  For all experiments mRNA expression was measured by 
real time PCR using an Applied Biosystems 7500 Real Time PCR System.  
Reactions consisted of 1x Mastermix, 0.9 µM forward and reverse primers, and 0.2 
µM dual-labeled fluorescent probes each for TRPV6 and β-actin.  The sequences of 
the forward and reverse primers for TRPV6 were 5′-GGT TCC TGC GGG TGG AA-3′ 
and 5′-CCT GTG CGT AGC GTT GGA T-3′ respectively, with the resulting amplicon 
being 62 bp with a Tm of 60°C.  The sequence of the probe for TRPV6 was 5′-ACA 
GGC AAG ATC TCA ACC GGC AGC-3′. The sequences of the forward and reverse 
primers for β-actin were 5′-CCT GGC ACC CAG CAC AAT-3′ and 5′-GCC GAT CCA 
CAC GGA ATA CT-3′ respectively, with the resulting amplicon being 69 bp with a Tm 
of 60°C. The sequence of the probe for β-actin was 5′-ATC AAG ATC ATT GCT CCT 
CCT GAG CGC-3′.  The specificity of all primers was confirmed by BLAST search.  
Primer Express (Applied Biosystems, Foster City, CA) was used for designing 
primers for TRPV6 and β-actin.  All primers were designed to cross exon-exon 
boundaries of the coding sequence.  Primers were optimized and validated for the 
comparative Ct method, as described in the manufacturer’s manual.  ABI Prism SDS 
software version 1 was used for the analysis of the amplification plots.  The TRPV6 
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expression values were normalized to β-actin and then compared.  The results are 
shown as fold change ± SD.  
 
Cell viability and apoptosis 
 
Cell viability experiments were carried out in 96-well culture plates with an initial cell 
number of 2500 cells per well to determine the influence of different hormones on 
cell growth. To determine the effect of siRNA on cell viability, the cells were seeded 
at 5000 cells per well.  After the cells were plated for 24 h, siRNA treatment was 
done for 72 h with 5 nM siRNA. Prior to optical density measurements, plates were 
kept continuously in cling film during incubation and the wells on the outer edge were 
not used for measurements.  After incubation time, the number of living cells was 
determined by the Cell Proliferation Kit II (XTT) (Roche) following the manufacturer’s 
instructions.  Briefly, 50 µl of XTT labeling mixture (including the electron-coupling 
reagent, N-methyl dibenzopyrazine methyl sulfate) was added to each well and 
plates were incubated for 4 h.  The absorbance was measured by an ELISA reader 
(Vmax microplate reader, Molecular Devices) at 450 nm with a reference wavelength 
at 650 nm. 
 
Apo-one homogenous caspase-3/7 assay (Promega, Madison, WI) was done 
according to manufacture’s protocol.  Cells and siRNAs were prepared as described 
above with the viability assay.  The profluorescent substrate was added to the cells 
for 3 hours before measuring the caspase activity on the Flexstation II (485 nm 
excitation and 527 nm emission).  The percentage of apoptotic cells was calculated 
relative to the untreated control cells.   
 
Ca2+ uptake activity measurement 
 
5000 cells per well were seeded in a black 96-well plate with 50 µl culture medium 
per well.  After cells have been plated for 24 h, siRNA treatment was performed with 
5 nM siRNA as described previously.  Subsequently, after 72 h the calcium uptake 
activity was observed in real-time using the FLIPR calcium 3 assay kit (Molecular 
Devices) according to the manufacturer’s manual.  Briefly, 50 µl of calcium free 
loading buffer was added to the cell medium.  Then 100 µl of calcium 3 dye was 
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added and incubated with the cells for 1 h at 37°C.  The plate was put into the 
Flexstation II, EGTA (5 mM final) was added to the cells to deplete intracellular 
calcium stores and finally calcium solution (10 mM final) was added to the cells to 
observe calcium entry.  Fluorescence units (RFU) per second was calculated from 
the slope of the uptake curve to show the calcium uptake activity after siRNA 
treatment.  Calcium uptake activity mediated by TRPV6 was also performed in 
Xenopus oocytes using 45Ca2+, as done previously (3). 
 
Reverse transcription PCR 
 
The Promega Access RT-PCR System was used according to the manufacturer’s 
instructions for detection of calcium channel expression in T47D cells.  After an initial 
heating step at 45°C for 45 min, the reactions were heated for 2 min at 94°C as a 
denaturing step. Subsequently, the cycle included a 30 second denaturing step, 
annealing at 60°C for 15 seconds, and extension reaction for 30 seconds at 68°C.  
24 cycles resulted in optimal linear amplification of products.  A final extension was 
done for 5 minutes at 68°C.  Samples were stored at -20°C before electrophoresis 
on a 1% agarose gel. 
 
The following primers were used: 
TRPC1A:  
forward 5′-TCTGCCCAAAGGCCATTG-3′ 
reverse 5′-GGGTATACTACTCTCCTCCATATTTTCTTC-3′ 
TRPC3:  
forward 5′-CGGCCGCACGACTATTTC-3′ 
reverse 5′-CCAGCCCCTTGTAGGCATT-3′ 
TRPC4: 
forward 5′-TGGCATGAAATATGGCTCAGTT-3′ 
reverse 5′-CGAGAGTTCTGATTCTGCTCTTACTATC  -3′ 
TRPC5:  
forward 5′-TGAGTTCAAGGCCGAGTATGAG-3′ 
reverse 5′-TCTCGATGGTTGAGGATGATCTC-3′ 
TRPC6: 
forward 5′-TTCTCCCATGATGTGACTCCAA-3′ 
reverse 5′-GAGGCCGTTCAATCCTAGCA-3′ 
TRPC7: 
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forward 5′-GGGCATGCTGAATTCCAAA-3′ 
reverse 5′-TCTGGTGGGCTTGCTCAAAG-3′ 
TRPV5: 
forward 5′-GCATTGTCAACTTCGCCTTC-3′ 
reverse 5′-GATCATTGTGGTTCTCAACC-3′ 
TRPV6:  
forward 5′-CCTGTGCGTAGCGTTGGAT-3′ 
reverse 5′-GGTTCCTGCGGGTGGAA-3′ 
 
Statistical data analysis 
 
Statistical significances between treatments and controls were analyzed with 
Student’s t-test using GraphPad Prism 3.0.  Differences in the comparison tests 
lower than p < 0.01 were considered significant.  
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Results 
 
In vitro TRPV6 knockdown 
 
The effect of TRPV6 knockdown on TRPV6 mRNA expression in T47D breast 
cancer cells was determined via real time PCR (Figure 1A). The TRPV6 messenger 
RNA level was significantly reduced in T47D cells after 72 hours by two different 
TRPV6 specific siRNA molecules. The most effective siRNA molecule was siRNA2, 
which reduced the TRPV6 message by 47%.  The siRNA1 had nearly the same 
effect on TRPV6 expression, subsequently reducing the mRNA by 40%.  The control 
siRNA did not significantly change TRPV6 expression and was comparable to 
untreated controls. 
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Figure 1. A, TRPV6 expression knockdown in T47D breast cancer cells after 72 hour treatment with 
two specific siRNAs (5 nM) and one siRNA control (5 nM), compared to one untreated control. TRPV6 
was measured by real time PCR and standardized via β-actin. 
 
After the treatment of T47D cells for 72 hours in 96-well plates with both siRNAs, the 
XTT viability assay was performed.  Figure 1B shows the percentage of growth 
reduction, measured as viable cells, of siRNA treated cells compared to control 
treated ones. The knockdown of TRPV6 led to a decrease in cell proliferation 
compared to siRNA treated controls, to 62% and 67%, respectively.  There was no 
effect of the control siRNA treatment on the growth of the T47D cells.  The anti-
estrogen tamoxifen (10 µM) comparatively reduced the number of viable cells to 34%, 
compared to vehicle only treated cells.  Dosing the cells with a combination of 
tamoxifen (10 µM) and siRNA1 (5 nM), in the presence of serum, diminished the 
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number of viable cells even further (19%), demonstrating more effectiveness than 
either treatment alone.   
0
20
40
60
80
100
120
veh
icle
 on
ly
con
trol
 siR
NA
siR
NA
1
siR
NA
2
tam
oxif
en
tam
oxif
en 
+ s
iRN
A1
%
 V
ia
bl
e 
ce
lls
 
Figure 1. B, TRPV6 expression knockdown effect on T47D breast cancer cell viability. Determination 
was performed with XTT viability assay 72 hours after siRNA (5 nM), tamoxifen (10 µM), or a 
combination of siRNA (5 nM) and tamoxifen (10 µM) treatment compared to siRNA control or vehicle 
only control. All treatments were done in presence of serum.  
 
The treatment of T47D cells with siRNA did not induce a large amount of apoptosis, 
as indicated by caspase-3/7 assay (Figure 1C).  Knocking down TRPV6 expression 
slightly increased the amount of apoptotic cells by 7%, compared to control siRNA.  
Both siRNAs had similar effects on apoptosis.  The treatment of cells with control 
siRNA produced a minimal increase in apoptotic cells, 4% more than the untreated 
control. 
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Figure 1. C, Apoptosis assay after treatment of T47D breast cancer cells with siRNAs (5 nM) for 72 
hours. Apoptosis was measure by caspase-3/7 assay. *p< 0.01, significant difference between 
untreated cells and control siRNA; **p<0.01, significant differences between control siRNA and 
TRPV6 siRNAs (two-tailed t-test).  
 
The reduced calcium channel activity after TRPV6 knockdown demonstrates that 
siRNA treatment affects the function of the channel and illustrates the importance of 
the channel in this cell line.  The knockdown led to a decrease in calcium uptake 
activity to 47% for siRNA1 and 48% for siRNA2, compared to control.  The uptake 
activity was measured in real-time and displayed in fluorescent units/sec (Figure 1D). 
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Figure 1. D, Calcium uptake activity measured by fluorescence-based FLIPR calcium 3 assay after 
72 hours of TRPV6 knockdown with siRNAs (5 nM). Calcium uptake activity is shown in fluorescent 
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units/sec measured as the slope of the uptake rates. *p< 0.01, significant differences between control 
siRNA and TRPV6 siRNAs (two-tailed t-test).  Columns, mean; bars, SD; N=3.   
 
 
TRPV6 expression in breast cancer   
 
To investigate the levels of TRPV6 expression in breast cancer tissues, a 
commercial cDNA panel was used to quantitate expression by real time PCR.  
Twelve cDNA samples from breast cancer tissue and eleven samples from normal 
mammary tissue were included in the analysis.  The majority of samples originated 
from invasive ductal carcinoma tissue (N=9), while sample #3 (invasive lobular 
carcinoma), sample #5 (invasive mixed tubular carcinoma), and sample #9 (adenoid 
cystic carcinoma) were the only exceptions.  The TRPV6 expression from the 11 
normal mammary tissues was averaged and used to compare expression from 
individual carcinoma tissue samples.  Thus, the data in figure 2 is represented as 
fold difference over normal.  From this analysis TRPV6 mRNA expression in 7 of 12 
patients was detected to be up-regulated between 2- and 15-fold over the average in 
normal breast tissue (Figure 2).  In 8 samples, TRPV6 transcript levels were 
upregulated on average 4.6-fold compared to the normal tissue average.  Further, 
the coefficient of variance (CV) of TRPV6 expression in normal breast tissue was 8% 
(N=11).  TRPV6 expression in the breast cancer samples was over twice as variable 
as in normal tissue, showing a CV of 17% (N=12).   
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Figure 2. TRPV6 mRNA expression in 12 breast cancer tissue samples compared to the average of 
11 normal samples based on real time PCR. TRPV6 was measured by real time PCR and 
standardized via β-actin. The data is represented as fold difference compared to the average 
expression from 11 normal breast tissue samples. Columns, mean; bars, SD; N=6. 
 
 
In vitro hormone effects on TRPV6 expression 
 
The most common treatments for breast tumors are hormonal treatments that act on 
the estrogen receptor to control breast cancer cell growth.  Therefore, we 
investigated whether estrogen and progesterone could regulate the expression of 
TRPV6.  The influence of these two hormones and controls on TRPV6 mRNA 
expression was determined via real-time PCR.  T47D cells were treated with 
different concentrations of estradiol, progesterone, and 1α,25-dihydroxyvitamin D3.  
Additionally tamoxifen, an estradiol receptor antagonist which is used in breast 
cancer therapy, and 5-fluorouracil, a compound used in several cancer therapies, 
were assessed for their affects on TRPV6 transcription regulation. 
 
Dose and time experiments were done to determine adequate concentration and 
treatment times. Figure 3 shows the TRPV6 mRNA expression compared to vehicle 
treated controls after 24, 48, and 72 hour treatments with estradiol (10 nM), 
progesterone (100 nM), a combination of both estradiol and progesterone, 1α,25-
dihydroxyvitamin D (100 nM), tamoxifen (1 µM), and 5-fluorouracil (1 µM).  After 24 
hours the effect of progesterone on TRPV6 expression was only slightly different 
compared to vehicle treated control.  A time dependent increase in expression was 
seen with estradiol after 24 hours, wherein after 72 hours the TRPV6 mRNA 
increased 69%. Treatment with progesterone also had a mild effect on increasing 
TRPV6 expression up to 56% after 72 hours.  Both hormones applied together 
stimulated induction of TRPV6 levels 96% over control when cells were treated for 
72 hours.   
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Figure 3. TRPV6 mRNA expression changes after treatment with estradiol (10 nM), progesterone 
(100 nM), both estradiol and progesterone, 1α,25 dihydroxyvitamin D (100 nM), tamoxifen (1 µM), and 
5-flurouracil for 24, 48, and 72 hours as determined by real time PCR.  Cells were starved of serum 
24 hours prior to treatment and kept without serum for the duration of the study.  Data is percent 
change compared to vehicle only treated cells.  Columns, mean; bars, SD; N=3.   
 
 
 
The estrogen receptor antagonist tamoxifen inversely affected TRPV6 expression at 
all time points tested.  Tamoxifen moderately reduced the TRPV6 mRNA by 31% at 
24 hours and was slightly less effective after 48 and 72 hours when used at 1 µM.  A 
log dose response study was performed with 24 hours of treatment time from which 
it was evident that reducing the tamoxifen concentration lessens the effect on 
TRPV6 mRNA (Figure 4A).  Dosing the cells with 10 µM tamoxifen reduced TRPV6 
mRNA by 35%. The highest dose tried with tamoxifen was 50 µM; however, the cells 
became apoptotic.  At 100 nM, tamoxifen only slightly reduced (12%) the TRPV6 
expression level.   
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Figure 4. A, Dose dependent effect of tamoxifen (100 nM, 10 nM, 1 nM, and 100 pM) on TRPV6 
mRNA expression in T47D cells after 24 hours determined via real-time PCR. Columns, mean; bars, 
SD; N=3. 
 
The hormone 1α,25-dihydroxyvitamin D (100 nM) was on its own far more potent at 
stimulating TRPV6 mRNA expression (114%) when the T47D cells were treated for 
24 hours (Figure 4B).  However, the stimulatory effect seen reduced over time and 
lead to only 39% induction after a 72 hour treatment.  A dose dependent relationship 
can be seen during a 24 hour treatment as seen in figure 4B. With log reductions of 
1α,25-dihydroxyvitamin D concentration, the stimulation effect nearly disappears at 
100 pM (14%). 
0
20
40
60
80
100
120
140
160
100nM10nM1nM100pM
%
 T
R
PV
6 
m
R
N
A
 
 
 42
Figure 4. B, Dose dependent effect of 1α,25 dihydroxyvitamin D (100 nM, 10 nM, 1 nM, and 100 pM) 
on TRPV6 mRNA expression in T47D cells after 24 hours determined via real time PCR. Data shown 
is percent change in TRPV6 mRNA compared to vehicle only control.  
 
As a control, 5-fluorouracil was used as another anticancer compound with an 
estrogen receptor independent mechanism (Figure 3).  After 24 hours with 5-
fluorouracil (1 µM), the treatment had no effect on TRPV6 mRNA level.  There was a 
slight upregulation, 14 and 21%, after 48 and 72 hours.    
 
Tamoxifen effect on TRPV6 calcium transport activity 
 
TRPV6 expressing oocytes were used to probe the inhibition effect of tamoxifen on 
calcium transport.  The drug showed a dose responsive blocking ability on TRPV6 
mediated 45Ca2+ uptake into oocytes (Figure 5).   Tamoxifen inhibits the channel with 
an IC50 value of 7.5 µM, which suggests that it may have an additionally beneficial 
mechanism to slow the growth of breast cancer cells. The IC50 value was determined 
using nonlinear data fitting (GraphPad Prism version 3.0).  
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Figure 5. Tamoxifen inhibits TRPV6 calcium transport activity of 45Ca2+ into Xenopus oocytes 
expressing TRPV6. Log dilutions of tamoxifen were used to inhibit TRPV6 mediated calcium uptake 
into oocytes. Columns, mean; bars, SD; N=6. 
 
Calcium channel expression in T47D cells 
 
To investigate the mRNA predominance of TRPV6 in T47D breast cancer cells, the 
expression of it and other calcium channels in this cell line were determined with 
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reverse transcription PCR and gel electrophoresis. Figure 6 shows the relative 
expression levels of the calcium channels: TRPC1, TRPC3, TRPC4, TRPC5, TRPC6, 
TRPC7, TRPV5, and TRPV6 in T47D cells.  From this analysis TRPC4, TRPC6, and 
TRPV6 are the most predominately expressed calcium channels on the RNA level.   
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Figure 6. Relative RNA expression levels of calcium channels as determined by semiquantitative RT-
PCR. MW (lane 1), TRPC1A (lane 2), TRPC3 (lane 3), TRPC4 (lane 4), TRPC5 (lane 5), TRPC6 (lane 
6), TRPC7 (lane 7), TRPV6 (lane 8), and TRPV5 (lane 9) in T47D cells. Amplicons range in size from 
100-150 bp. 
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Discussion 
 
The TRPV6 calcium entry channel has previously been shown to be linked to 
prostate tumor progression and development.  The role of TRPV6 in the progression 
of tumor cells is not completely clear, but appears to involve accumulation of cellular 
calcium to promote cancer cell growth or survival.   
 
Previously, it has been demonstrated that TRPV6 appeared to be upregulated on the 
protein level in breast adenocarcinoma tissue (8).  In this report we further 
investigated the expression level of TRPV6 in breast cancer tissue from patients as 
compared to normal mammary tissue.  In the 12 patient samples analyzed by real 
time PCR, 8 samples had TRPV6 transcript levels that were upregulated on average 
4.6-fold compared to the normal tissue average.  This further strengthens our earlier 
observation where we seen upregulation on the protein level (8).  There are 
associated ER and PR values for each cancer tissue sample (data not shown), but 
we were unable to find any clear, statistically significant correlation between these 
values and TRPV6 expression.   
 
We investigated this relationship under more controlled conditions to see how 
estrogen receptor may regulate TRPV6 in breast cancer cells in vitro.  When 
stimulated with estrogen for 24 hours, the RNA transcript of TRPV6 was slightly 
reduced as compared to vehicle only treated cells.  Likewise, when prostate cancer 
cells were treated with dihydrotestosterone for a similar period of time, the 
transcription of TRPV6 also decreased (7).  In contrast, when activated longer with 
estrogen from 48 to 72 hours, the cells increased the transcription of TRPV6 up to 
69%.  It has long been known that estrogen promotes T47D cell proliferation (23, 24).  
Long term upregulation of TRPV6 appears to be part of this cell growth mechanism.  
The anti-estrogen, tamoxifen showed interesting activity upon TRPV6 expression at 
all time points tested.  Blocking the estrogen receptor with tamoxifen caused the 
TRPV6 transcript levels to reduce.  The limited signaling that can occur from ER 
seems to lead to lower TRPV6 expression.  And with increasing concentrations of 
tamoxifen, this effect becomes even more pronounced.  These observations suggest 
that the ER is able to regulate TRPV6 expression to possibly promote increased 
calcium entry into the cells.  When used at low concentrations (0.1-1 µM) tamoxifen 
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has been shown to induce G1 cell cycle arrest in T47D cells, thereby stopping cell 
proliferation (23, 25).  Correspondingly the T74D cells reduced TRPV6 expression, 
which acts negatively to inhibit the cell growth.  Larger doses of tamoxifen over 5 µM 
have been reported to induce apoptosis in T47D cells (26).  In our studies we have 
observed that the activity of tamoxifen was enhanced by knocking down TRPV6 
expression.  We would expect a stronger enhancement if the expression was further 
knocked down.  However, affecting the channel activity may be done more 
effectively through designing TRPV6 specific chemical inhibitors.  These studies 
demonstrate that a combination therapy using tamoxifen and a TRPV6 inhibitor 
would be a beneficial approach to treating breast cancer cells.     
 
Estrogen is known to induce increased calcium absorption via upregulating TRPV6 
in female mouse intestine via a vitamin D independent mechanism (6).  During 
pregnancy the increased calcium absorption is needed to compensate for increased 
nutritional demands.  Likewise, 1,25-vitamin D is also a known TRPV6 stimulator as 
shown in this study and previous studies (27).  At low concentrations (0.05 nM-0.8 
nM) vitamin D promotes growth (28), whereas increasingly higher concentrations 
cause cell cycle block in G1 phase and subsequent apoptosis (29) (30).  In our 
experiments, we see that TRPV6 expression reduces significantly after 24 hours 
after 1,25-vitamin D (100 nM) treatment.  Thus, this effect seems to be in 
coordination with the T47D cell reducing its proliferation. 
 
Additionally, we observed that tamoxifen can not only downregulate TRPV6 mRNA 
expression, but it can directly inhibit the calcium channel activity.  We observed this 
affect when we expressed TRPV6 in Xenopus oocytes, giving an IC50 value of near 
7.5 µM.  This is intriguing given the fact that it is an estrogen receptor inhibitor.  
However, it does share several structural similarities with known T-type calcium 
channel inhibitors such as a tertiary nitrogen, aromatic groups, and an ether bond.  
In support of this, it can be found in the literature that both tamoxifen and raloxifene 
are able to affect calcium channel activity.  In whole cell patch clamp studies in 
vascular smooth muscle cells, tamoxifen reduced the current through L-type calcium 
channels with an ID50 of 2 µM and through T-type channels 10 µM (31).  The anti-
estrogen SERM, raloxifene, is also known to affect voltage sensitive L-type calcium 
channel activity (32) (33, 34).   
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Tamoxifen is also known to be effective in ~10% ER and PR negative patients (19, 
20).  This might suggest that tamoxifen is directly acting on the TRPV6 calcium 
channel in those patients.  Therapeutic concentration of tamoxifen in the breast 
cancer tissue can reach low µM values (35). Therefore, IC50 concentration for 
TRPV6 inhibition measured in oocytes is in a similar range to what has been seen in 
tumor tissues, and thus may be clinically relevant in the affect of the drug.  
Regardless, it would be interesting to collect data on TRPV6 expression along with 
receptor values when assessing the effectiveness of tamoxifen in patients.  More 
specific TRPV6 inhibitors could be employed to regulate the growth of breast tumor 
cells expressing TRPV6. 
 
In the T47D breast cancer cells, TRPV6 is one of several potential calcium entry 
channels expressed, but TRPV6 is the only calcium specific entry channel present.  
The importance of TRPV6 could be seen after siRNA knockdown studies, since the 
proliferation rate of the cancer cells was reduced by 60% and calcium transport was 
reduced by 50%.  Importantly, the siRNA knockdown of TRPV6 was not complete in 
these experiments, so the full influence in these cells could not be fully assessed.  
There are two other potential calcium permeable channels, TRPC4 and TRPC6, 
which could also be contributing to the calcium uptake into these cells.  However, 
these channels are receptor-operated, nonselective cation channels (36).  
Specifically, TRPC6 behaves as a nonselective cation channel that is activated by 
diacylglycerol in a membrane-delimited fashion, independently of protein kinase C 
(37). The TRPC6 channel is not considered to be store-operated and only has 
limited Ca2+ permeability relative to monovalent cation permeability (38).  We cannot 
rule out their contributions at this time, but our results indicate that TRPV6 has a 
major influence on cellular calcium entry. 
 
The breast cancer cells used in this study were slowed by reduced calcium channel 
expression and lower calcium uptake potential.  The stable expression of TRPV6 in 
the kidney cell line HEK-293 promoted increased cellular proliferation and calcium 
accumulation (15).  Clearly, the calcium state inside cells can influence their 
proliferation rate.  Furthermore, previous studies in prostate cancer cell lines indicate 
that TRPV6 plays a significant role in prostate cancer calcium influx (39, 40).   
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In T47D cancer cells, TRPV6 also contributes a rather significant portion of the 
calcium entry activity and leads to a large reduction (~60%) in the proliferative ability 
of the cells.  Further, it was found that treatment with TRPV6 specific siRNAs 
produced a small increase (~7%) in apoptosis in the breast cancer cells, as indicated 
by a caspase-3/7 assay.  Therefore, the net result indicates that the cancer cells are 
growing less rapidly, rather than dying from reduced calcium uptake.  Silencing 
TRPV6 in the breast cancer cells may be causing cell cycle arrest, which may 
explain the less rapid cell proliferation.  We have not provided direct evidence for this, 
but it has been shown that TRPV6 silencing in the prostate cancer cell line, LNCaP, 
results in a reduced number of cells entering S-phase (39).  Similar to our study, the 
LNCaP cells show a higher rate (~15%) of apoptosis after specific TRPV6 siRNA 
knockdown (39).  From their study in LNCaP it was suggested that calcium entry via 
TRPV6 not only maintains an increased proliferation rate, but increases cellular 
survival and provides resistance to apoptosis.  Here we see similar results; however, 
in T47D cells TRPV6 seems to provide less resistance to apoptosis.  This may be 
due to the presence of TRPC4, TRPC6, or other entry channels permeable to 
calcium or insufficient TRPV6 knockdown.  Therapeutic treatments aimed at 
inhibiting the TRPV6 channel would thus keep the cancer cells from rapidly growing.  
For instance, it has been shown that calcium channel inhibitors that likely block 
TRPV6 are able to restrict the growth of prostate cancer cells in a cytostatic manner 
and when administered to mice show no toxicity (41). 
 
In this study we have shown that TRPV6 is expressed at elevated messenger levels 
in breast cancer patient samples.  In our in vitro model, estrogen, progesterone, and 
1,25-vitamin D were all able to regulate TRPV6 transcription.  Interestingly, 
tamoxifen acts negatively on two levels to reduce both the expression and activity of 
TRPV6.  This suggests that TRPV6 might be involved in the antiproliferative activity 
of the widely used breast cancer treatment tamoxifen.  However, further clinical data 
would be needed to address this hypothesis.  Regardless, TRPV6 appears be able 
to control the proliferative ability of T47D breast adenocarcinoma cells.  The activity 
of tamoxifen was enhanced by combination treatment with TRPV6 silencing siRNA.  
Our studies indicate that TRPV6 may be suitable target for development of specific 
chemical inhibitors.  Furthermore, when hormonal therapies are no longer effective, 
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inhibitors for TRPV6 may be of increased value particularly when the tumors become 
ER or PR negative.   
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ABSTRACT 
The epithelial calcium channel TRPV6 is up regulated in breast carcinomas 
compared to normal mammary gland tissue. The selective estrogen receptor 
modulator tamoxifen is widely used in breast cancer therapy. Previously, we showed 
that tamoxifen inhibits calcium uptake in TRPV6-transfected Xenopus oocytes. In 
this study, we examined the effect of tamoxifen on TRPV6 function and intracellular 
calcium homeostasis in MCF-7 breast cancer cells transiently transfected with 
EYFP-C1-TRPV6. TRPV6 activity was measured with fluorescence microscopy 
using Fura-2. The basal calcium level was higher in transfected cells as compared to 
non-transfected cells in calcium containing solution but not in nominally calcium free 
buffer. Basal influxes of calcium and barium were also increased. In transfected cells, 
10 µM tamoxifen reduced the basal intracellular calcium concentration to the basal 
calcium level of non-transfected cells. Tamoxifen decreased the transport rates of 
calcium and barium in transfected cells by 50%. This inhibitory effect was not 
blocked by the estrogen receptor antagonist, ICI 182,720. Similarly, a tamoxifen 
induced inhibition effect was also observed in MDA-MB-231 estrogen receptor 
negative cells. The effect of tamoxifen was completely blocked by activation of 
protein kinase C. Inhibiting PKC with calphostin C decreased TRPV6 activity but did 
not alter the effect of tamoxifen. These findings illustrate how tamoxifen might be 
effective in estrogen receptor negative breast carcinomas and suggest that the 
mechanisms of tamoxifen and PKC inhibitors used in breast cancer therapy might 
involve TRPV6 mediated calcium entry. This study highlights a possible role of 
TRPV6 as therapeutic target in breast cancer therapy.  
Key words: TRPV6, epithelial calcium channel, tamoxifen, breast cancer, estrogen 
receptor, cancer therapy 
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INTRODUCTION 
 
Breast cancer is still ranked third among all cancer deaths and had the highest 
incidence rate of all cancers of both sexes in Europe in 2006 (190). The survival 
chances of breast cancer patients depend to a great extent on the expression level 
and responsiveness of steroid hormone receptors in cancer tissues. Tumors that are 
estrogen (ER) and progesterone receptor (PR) positive have a higher treatment 
success than those which are non-responsive to estrogen and progesterone (191). 
The most widely used anti-estrogen therapy is the application of tamoxifen, which 
belongs to the selective estrogen-receptor modulators. Tamoxifen competitively 
inhibits estradiol binding to the ER and evokes a series of events such as 
conformational changes of the ER and dimerization and dissociation of heat shock 
proteins. This triggers binding of the ER to estrogen responsive elements and 
transcriptional regulation. Additionally, many coregulator proteins can interact with 
the ER, but the exact mechanism of how tamoxifen effects the tumors and what role 
calcium plays in this process is not yet completely understood (192). There is also 
evidence that tamoxifen is cytotoxic for estrogen receptor negative breast cancer 
cells and that it can be effective in one-third of estrogen receptor negative tumors 
(46; 102). A study by Bollig et al., 2007, showed that tamoxifen up regulates protein 
phoshatase 1 alpha (PP1alpha) via an estrogen receptor independent pathway (193). 
Altered changes in intracellular Ca2+ were shown to be induced by tamoxifen at 
micromolar concentrations and to trigger death of breast cancer cells (45; 60; 97; 
139). 
Changes in intracellular calcium homeostasis are a crucial step in tumor formation in 
every type of cancer because they influence several cellular functions such as 
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cellular motility, differentiation, proliferation, and apoptosis. Furthermore, calcium is a 
key regulator of the cell cycle (194). Interestingly, there is an up- or downregulation 
of specific calcium channels or pumps associated with certain types of cancer. For 
instance, the plasma membrane ATPase 2 (PMCA2) is overexpressed in certain 
breast cancer cell lines such as ZR-75-1 compared to non-tumorigenic 184B5 cells 
(Monteith et al., 2005). In prostate cancer tumors, the expression level of TRPM8 
mRNA is significantly increased in malignant tissue compared to healthy tissue 
(Fuessel et al., 2003). One other example is the altered expression of TRPV6 in 
prostate, pancreatic, thyroid, colon, ovary, and breast cancer (195). 
TRPV6 belongs to the transient receptor potential (TRP) channels. The “TRPV” 
vanilloid subfamily comprises six channels of which TRPV5 and TRPV6 are relatively 
selective epithelial calcium channels expressed in renal tubular cells or in the apical 
membrane of enterocytes, respectively. TRPV6 was discovered in 1999 in rat 
duodenum using expression cloning (196). Structurely, TRPV6 comprises 730 amino 
acids and contains six transmembrane domains and a short hydrophobic region 
between TM5 and TM6, which functions as the pore-forming region. The COOH 
terminus contains a calmodulin binding site and the NH2 terminus has several 
ankyrin repeats on the intracellular side (120). TRPV6 is predominantly expressed in 
the duodenum where calcium is absorbed. In situ hybridization showed localization 
in the epithelial cells and on the villi tips (195). Additionally, TRPV6 expression was 
detected in pancreatic acinar cells, in mammary gland duct cells, sweat glands, skin, 
and placenta (197). Examination of TRPV6 transport by electrophysiology revealed 
that the channel mediates passive Ca2+-transport with high calcium selectivity and an 
apparent Km value for Ca2+ of 0.44mM. The cation permeability decreases in the 
order Ca2+ > Ba2+ > Sr2+ > Mn2+ (198). At the present time, there is no selective 
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blocker for TRPV6 mediated calcium influx available. Non-specific blockage with 
ruthenium red, Gd3+, and La3+ was observed (199). TRPV6 mRNA expression is 
regulated by dietary calcium, 1,25-vitamin D3, dihydrotestosterone, and estrogen 
(133; 156; 178). The intestinal calcium absorption is significantly reduced in TRPV6 
knockout mice (9). This demonstrates the importance of TRPV6 as a major calcium 
uptake pathway of dietary calcium in the intestine.  
The exact function of TRPV6 in exocrine tissues is still unknown and its role in 
cancer is not clear thus far. Numerous studies are published on the role of TRPV6 in 
prostate cancer. A correlation of TRPV6 expression to the prostate cancer Gleason 
grade was detected in different cancer stages, whereas there was only little 
expression in normal prostate tissue (200). Furthermore, certain prostate cancer cell 
lines like LNCaP and PC-3 express high amounts of TRPV6 mRNA (201). A study in 
LNCaP cells demonstrated that TRPV6 can influence the proliferation rate, the cell 
cycle, and the expression of the proliferating cell nuclear antigen (PCNA). TRPV6 is 
the main channel responsible for calcium uptake in this cell line and it can activate 
the nuclear factor of activated T-cells (NFAT). Lehen'Kyi et al demonstrated in the 
same study that the androgen receptor is involved in TRPV6 regulation in a ligand-
independent way. They found that AR knockdown by siRNA decreased TRPV6 
mRNA and protein levels, but the ligands DHT, an AR-selective agonist, and 
Casodex, a selective antagonist, had no significant effect on TRPV6 mRNA 
expression (202).  
This confirms earlier results of studies using HEK293 cells, which revealed an 
increased proliferation rate if the cells were stably expressed with TRPV6 (203). Of 
great importance is the fact that TRPV6 mRNA and protein expression is not only 
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increased in prostate cancer, but also in human carcinomas of the colon, thyroid, 
ovary, and breast (133; 195; 208). 
In the ductal epithelial cells of the mammary gland, TRPV6 was found to be 
expressed in the apical membrane (195).  
Our former study confirmed that TRPV6 is expressed at higher levels in breast 
cancer samples compared to non-tumorous samples (204). We also showed that 
TRPV6 expression in T47D breast cancer cells is increased by estrogen, 
progesterone, and 1,25-vitamin D3. In contrast, tamoxifen was found to 
downregulate TRPV6 expression in cancer cells and to inhibit radioactive calcium 
uptake into TRPV6-expressing Xenopus oocytes. Therefore, TRPV6 might be 
involved in the mechanism of tamoxifen in breast cancer cells. In T47D cells, TRPV6 
is able to control proliferation as we showed using the siRNA expression knockdown. 
The studies indicated that it might be clinically useful to develop specific TRPV6 
inhibitors as breast cancer drugs. Especially, in the case of estrogen receptor 
negative tumors, TRPV6 targeting could be promising (205).  
As a continuation of our published article on the role of TRPV6 in breast cancer, in 
the present study, our goal was to demonstrate the inhibitory effect of tamoxifen on 
TRPV6 mediated calcium uptake in breast cancer cells and to investigate the 
mechanism and the subsequent effect on intracellular calcium homeostasis. Our 
findings help to clarify a potential mechanism of how tamoxifen may be useful in 
breast cancer therapy. 
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RESULTS 
 
Expression of TRPV6 in MCF-7, T47D ER+ and MDA-MB-231 ER- breast cancer 
cells 
 
First, we tested the expression of TRPV6 mRNA in three widely used human breast 
cancer cell lines. TRPV6 mRNA was found to be expressed at a high level in T47D 
cells whereas MCF-7 and MDA-MB-231 cells showed very low levels of TRPV6 (Fig. 
1A). The amount of TRPV6 mRNA expressed in T47D was comparable to the mRNA 
level in LNCaP prostate cancer cells (data not shown). Immunoprecipitation of 
TRPV6 followed by Western blot technique revealed that T47D cells express higher 
levels of TRPV6 protein compared to the other two cell lines (Fig. 1B). When we 
examined the level of the expressed TRPV6 protein qualitatively in these three cell 
lines using immunofluorescence microscopy, our observation was similar as shown 
in Fig. 1C. 
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Figure 1: (A) Comparison of TRPV6 mRNA expression (fold difference) in MCF-7, MDA-MB-231 cells 
and T47D human breast cancer cells detected with real-time PCR. (B) Comparison of TRPV6 protein 
in T47D, MDA-MB-231, and MCF-7 cells measured with immunopreciptiation and Western blotting. 
(C) Phase contrast images (left) and immunofluorescence staining (right) of TRPV6 in MDA-MB-231 
cells (a,b),MCF-7(c,d), and T47D cells (e,f). Images were taken with a 20x objective (scale bar 20 µM). 
 
Furthermore, in T47D cells TRPV6 showed co-localization with PMCA, suggesting 
that it is expressed at the plasma membrane (Fig. 2). 
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Figure 2: Immunofluorescence double staining with anti-TRPV6 (A) and anti-PMCA antibodies (B) in 
T47D cells. Arrows point at the co-localization of TRPV6 and PMCA in the merged (C) image. The 
overlay of the phase contrast and the merged image is presented on Panel D. Images were taken 
with a 20x objective (scale bar 20 µM). 
 
Effect of tamoxifen on calcium entry in T47D cells  
 
The basal calcium influx was determined by measuring the rate of the increase of the 
fura-2 fluorescence ratio following administration of 1 mM calcium. In T47D cells, this 
calcium influx was very small (Figs. 3A and 3C). When we investigated the effect of 
10 µM tamoxifen on basal calcium influx, we found a remarkable increase in calcium 
entry (Figs. 3B and 3C). Additionally, tamoxifen induced a large transient rise in 
intracellular calcium in nominally calcium-free buffer (Fig. 3B).  
A B
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Fig. 2
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Figure 3: Representative tracings (Panel A, and B) and bar graph (Panel C) showing the effect of 10 
µM tamoxifen citrate on basal barium and calcium influxes in T47D cells. Number of separate 
experiments >6; *, p<0.05. 
 
This effects can be explained by the fact that tamoxifen induces calcium depletion of 
the endoplasmic reticulum calcium stores which in turn activate store-operated 
calcium channels (SOCCs) expressed in the plasma membrane. This phenomenon 
was observed in several other cell types. Unfortunately, the activation of SOCCs 
masks any possible effect of tamoxifen on TRPV6. Therefore, we had to turn to 
another approach namely overexpressing EYFP-tagged TRPV6 in MCF-7 cells. 
 
Effect of tamoxifen on TRPV6 mediated calcium entry calcium entry in MCF-7 cells  
 
MCF-7 cells were chosen for transfection of TRPV6 because they express only very 
low levels of endogenous TRPV6 (Fig. 1A). Confocal, fluorescence images of 
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transfected MFC-7 cells suggested that exogenous TRPV6 is expressed at the 
plasma membrane (Fig. 4 arrows).  
A B
Fig. 4
 
Figure 4: Phase contrast (A) and fluorescence EYFP-image (B) to display localization of EYFP-C1-
TRPV6 after transient transfection in MCF-7 cells. Images were taken with a 60x objective (scale bar 
20 µM). Arrows point at plasma membrane localization. 
 
The transfected cells were identified based on EYFP fluorescence (Fig. 5A und 5B).  
A
B C
Fig. 5
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Figure 5: Phase contrast image (A), EYFP-image (B), and Fura-2 ratio image (C) of EYFP-C1-TRPV6 
expressing MCF-7 cells. Note that TRPV6 expressing cells have higher basal intracellular calcium 
level.  
 
As expected, the basal intracellular calcium concentration was highly increased in 
transfected cells, compared to non-transfected cells (ratio of 2.027 ± 0.023 vs 1.23 ± 
0.004; P < 0.001) (Figs. 5C, 6A and 6B). When extracellular calcium was omitted this 
difference was no longer detectable (1.16 ± 0.004 vs 1.116± 0.002). Furthermore, 
basal calcium and barium influx was 100- and 9- fold larger in transfected cells 
compared to non-transfected cells, respectively (Figs. 6C and 6D). 
Basal intracellular calcium concentrations and the basal calcium influx rate 
correlated closely, as shown in Figs. 6E and 6F. Both of the influxes were almost 
completely inhibited by 100 µM Gd3+, a non-specific TRPV6 inhibitor (data not 
shown). Our functional data and confocal images provided solid evidence that the 
expressed EYFP-TRPV6 is fully functional at the plasma membrane.  
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Figure 6: Representative tracings showing Ca2+ (Panel A), Ba2+ (Panel B) influxes in MCF-7 cells 
using the Ca2+-sensitive fluorescent dye fura-2. First, extracellular Ca2+ was removed followed by 
administration of 1 mM external Ca2+ or Ba2+ when the fura-2 ratio was stabilized. The rate of the 
increase of the fura-2 ratio in response to re-addition of the particular divalent cation was analyzed. 
Summary data in Panels C and D show the rate of changes in Fura-2 ratio after re-addition of calcium 
or barium w/o 10 µM tamoxifen citrate treatment for 10 min in transfected and non-transfected cells. 
Panels E and F depict the correlation between basal calcium or barium entry and normal intracellular 
calcium concentration in transfected cells. *, p<0.05 control vs tamoxifen group. 
 
Incubation with 10 µM tamoxifen for 10 minutes induced a transient calcium increase 
followed by a sustained decrease in intracellular calcium. The intracellular calcium in 
transfected cells finally reached the calcium level of non-transfected cells (Fig. 7A). 
In nominally calcium free medium, the tamoxifen-induced calcium increase was 
reduced to insignificant levels (Fig. 7B).  
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Figure 7: Representative tracings showing the effect of 10µM tamoxifen citrate on intracellular [Ca2+] 
([Ca2+]i)  in EYFP-C1-TRPV6 expressing MCF-7 cells  in the presence of 1 mM extracellular Ca2+  (A) 
or in nominally calcium free solution (B). 
 
The application of 10 µM tamoxifen for 10 min induced a prominent decrease in 
initial calcium and barium influx rate down to 37.6% (ratio of 440.84 ± 45.84 vs. 
165.77 ± 26.39), respectively 39.7% (ratio of 90.75 ± 9.00 vs. 36.04 ± 3.20) (Fig. 6C 
and 6D). Tamoxifen at 1 µM for 1h also decreased TRPV6 activity to 24.4 % (ratio of 
440.84 ± 45.84 vs. 107.63 ± 16.04) but not when applied for 10 minutes (Fig. 8). 
Furthermore, the tamoxifen metabolite, 4-hydroxy-tamoxifen (10 µM for 10 min), 
decreased TRPV6 activity to 17.77% (ratio of 440.84 ± 45.84 vs. 78.32 ± 13.74) (Fig. 
8).  
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Figure 8: Summary data show the rate of changes in the fura-2 ratio after re-addition of calcium in 
control group and in response to treatment with 1 µM, 10 µM tamoxifen (Tam), and 10 µM 4-hydroxy-
tamoxifen (4-H-Tam) treatment for 10 min and with 1 µM and 10 µM tamoxifen treatment (Tam) for 1h 
in MCF-7 cells transfected with TRPV6. *, p<0.05 treatment vs control group 
 
 
Determination whether the estrogen receptor is involved in the observed effect of 
tamoxifen  
 
When the estrogen receptor antagonist ICI 182,780 (1 µM) was applied together with 
tamoxifen to MCF-7 cells, we observed no significant change of the tamoxifen 
induced inhibition in the presence of ICI 182,780 (Fig. 9A). To confirm these findings, 
we examined the effect of 10 µM tamoxifen in the estrogen receptor negative, human 
breast cancer cell line, MDA-MB-231, transiently transfected with EYFP-C1-TRPV6. 
Tamoxifen exerted a similar effect like in transfected MCF-7 cells. The initial calcium 
influx was decreased to 30.5% by tamoxifen in transfected cells compared to the 
control group (ratio of 542.28 ± 157.58 vs. 165.73 ± 32.29) (Fig. 9B). 
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Figure 9: (A) Summary data showing the effect of a pretreatment in transfected MCF-7 cells with the 
estrogen receptor antagonist ICI 182.780 (1 µM) for 10 min on TRPV6 activity with and without 
tamoxifen. Data are the means of at least 25 cells from 6 separate experiments. (B) Summary data 
showing the effect of 10 µM tamoxifen on calcium influx in estrogen receptor negative MDA-MB-231 
cells *, p<0.05 control vs tamoxifen group. 
 
Determination whether PKC plays a role in the observed effect of tamoxifen  
 
Since tamoxifen was shown to affect protein kinase C (PKC) activity in MCF-7 cells 
and several possible serin/threonine phosphorylation sites can be predicted on 
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TRPV6, we tested whether PKC inhibition could be involved in the effect of 
tamoxifen on TRPV6 activity (206). We found that activation of PKC with 200 nM 
PMA promptly elevated intracellular calcium in transfected cells, whereas the effect 
was much smaller in non-transfected cells. Furthermore, in some transfected cells, 
slow calcium oscillations could be observed (Fig. 10A). When extracellular calcium 
was removed, this robust calcium increase vanished. Also, basal calcium influx was 
significantly increased in the transfected cells (Fig. 10A). The inhibitory effect of 
tamoxifen was completely abolished in the presence of PMA (Fig. 10B). When we 
applied the PKC inhibitor calphostin C (100 nM), we observed that calphostin C 
alone or in combination with tamoxifen decreased the initial calcium influx in 
transfected MCF-7 cells to 50.4% and 46.4%, respectively (from 440.84 ± 45.84 to 
178.57 ± 21.99, to 204.34 ± 30.56) (Fig. 10B) . Therefore, tamoxifen exerted no 
additional inhibitory effect when PKC was inhibited. 
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Figure 10: Panel A: Representative tracings showing changes in the calcium increase induced by 
inhibition of PKC with 200 nM PMA for 10 min. Panel B: Summary data showing the effect of the PKC 
activator PMA (200 nM) and the PKC inhibitor calphostin C (100 nM) on the inhibitory effect of 10 µM 
tamoxifen in MCF-7 cells transfected with TRPV6. Cells were pre-treated with calphostin C for 1h. 
Data are the means of at least 25 cells from 6 separate experiments. *, p<0.05 treatment vs control 
group  
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DISCUSSION 
 
In spite of intensive efforts towards development of novel therapeutic approaches for 
the prevention and treatment of breast cancer, the incidence rate of breast 
adenocarcinomas is still highest among all cancer types and the mortality rate was 
3rd among all cancers in Europe in 2006 (207). Since intracellular calcium plays a 
critical role in many fundamental cellular processes such as proliferation, apoptosis, 
and secretion, calcium levels are spatially and temporally tightly controlled in cells. 
Disturbances in intracellular calcium homeostasis are a crucial factor in the process 
of tumor progression in all cancer types. Many studies have been conducted to 
evaluate how the regulatory system of intracellular calcium homeostasis and the 
associated calcium signaling pathways are altered in breast cancer cells compared 
to normal mammary gland cells. A recent review summarizes the possible roles of T-
type calcium channels in breast cancer progression (208). The essential roles of the 
store operated calcium channel Orai1 and the signaling molecule Stim1 in breast 
cancer metastasis formation was recently reported (209).  Monteith and his group 
observed that the expression of different isoforms of the PMCA is changed in breast 
cancer cells and that PMCA2 expression is significantly increased (83; 84). 
Furthermore, inhibition of PMCA using siRNA decreased proliferation of MCF-7 
human breast cancer cells (210). In recent years, there has been accumulating 
evidence that the TRPV6 epithelial calcium entry channel is involved in breast 
cancer progression. In human and mouse breast cancer samples, TRPV6 protein 
expression was increased (195).  
In addition, our laboratory recently demonstrated that a knockdown of TRPV6 
expression using siRNA decreased basal calcium influx and proliferation of T47D 
 71
human breast cancer cells (211). As a novel finding, we also found that tamoxifen, at 
micromolar levels, inhibits TRPV6-mediated calcium influx in human TRPV6-
expressing Xenopus oocytes. In the present study, we addressed the mechanism of 
this inhibitory effect and its consequences on intracellular calcium homeostasis using 
transfected breast cancer cell lines.  
We selected two widely used human, estrogen receptor positive breast cancer cell 
lines, T47D and MCF-7, and MDA-MB-231 which are estrogen receptor negative. 
First, we examined the expression of TRPV6 in these cell lines. The mRNA levels 
were low in MCF-7 and MDA-MB-231 and high in T47D cells. The expression of 
TRPV6 in T47D cells was comparable to LNCaP prostate cancer cells which are 
known to have high TRPV6 levels (data not shown). Immunofluorescence staining, 
and Western blotting of immunoprecipitated samples also showed much higher 
expression of TRPV6 in T47D cells compared to MCF-7 or MDA-MB-231 cells. 
Unfortunately, in T47D cells, a high dose of tamoxifen above 1 µM induced depletion 
of the ER calcium stores followed by a robust increase in store-operated calcium 
channel (SOCC) activity. Since, in non-depolarizing cells, the majority of the basal 
calcium influx occurs through SOCC, the possible effect of tamoxifen on native 
TRPV6 activity was masked. Tamoxifen also exerts the same effect on SOCC 
activity in several cell types such as human oral cancer cells, CHO-K1 cells, human 
osteosarcoma cells, and ZR-75-1 human breast cancer cells (32; 37; 76; 95). This 
effect was shown not to be mediated by estrogen receptors.  
To evaluate the effect of tamoxifen on TRPV6, we increased the number of TRPV6 
channels residing in the plasma membrane of the MCF-7 cells, which expresses a 
low level of endogenous TRPV6. To this end, we over-expressed EYFP-tagged 
human TRPV6 in MCF-7 cells to reach expression levels of TRPV6 comparable to 
 72
those of SOCCs. In such TRPV6 over-expressing cells, we observed a significantly 
higher basal calcium level and increased calcium and barium influxes. Confocal 
immunofluorescence studies confirmed that TRPV6 is expressed at the plasma 
membrane. A short, 10 minute incubation of 10 µM tamoxifen induced a much higher 
transient calcium response in transfected cells compared to non-transfected cells, 
the effect of which was diminished when extracellular calcium was omitted.  
It should be noted that we selected this initial tamoxifen concentration because the 
IC50 value of tamoxifen was 7.5 µM in Xenopus oocytes (212).  
In transfected MCF-7 cells, after transient calcium elevation, basal intracellular 
calcium returned to the same level as in non-transfected cells. As described above, 
this temporary calcium elevation is probably due to ER calcium store depletion and 
subsequent activation of SOCCs. In transfected cells, both basal calcium and barium 
influxes were reduced by tamoxifen to 37.6% and 39.7%, respectively. In non-
transfected cells, there was either no effect (barium influx) or a small increase 
(calcium influx) in response to tamoxifen. 10 µM hydroxy-tamoxifen and prolonged 
incubation with lower (1 µM) dose of tamoxifen also reduced TRPV6 mediated 
calcium influx, suggesting that in tamoxifen-treated breast cancer patients, inhibition 
of TRPV6 could be involved in the anti-tumor effect of tamoxifen. After treatment of 
patients with 5 or 20 mg tamoxifen citrate daily for 28 days the concentration of 
tamoxifen can reach between 0.73 µM and 2 µM in the breast cancer tissue (213). In 
our experiments we used 10 µM tamoxifen and to further ensure the physiological 
significance also a lower concentration of tamoxifen (1 µM).  
As we expected, estrogen receptors were not involved since inhibition of estrogen 
receptors with ICI 182,780 in ER+ MCF-7 cells was ineffective. Also, tamoxifen 
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reduced TRPV6 activity in the ER negative cell line, MDA-MB-231, to the same 
extent as in the ER positive cell line, MCF-7.  
Previously, it was shown that tamoxifen is a potent PKC inhibitor in vitro (214). 
However, in MCF-7 cells, the reported findings on the effect of tamoxifen are 
controversial. Rowlands et al tested the inhibitory potential of several tamoxifen 
analogues in MCF-7 cells (215). In 2003, one group observed a reduction of PKC 
activity by tamoxifen, whereas in another report, an increased PKC activity and 
induction of PKC translocation to the plasma membrane in response to tamoxifen 
was observed (18; 22). The phosphorylation of T702 on TRPV6 by PKC was also 
demonstrated by Flockerzi and his group (216). This threonine residue is localized in 
the calmodulin binding site of TRPV6. Phosphorylation at this position blocks 
inactivation of the channel by calcium-calmodulin complex. In our experiments, 
activation of PKC by PMA completely abolished the inhibitory effect of tamoxifen on 
TRPV6. When the PKC inhibitor calphostin C (100nM) was applied, TRPV6 activity 
was diminished. Furthermore, tamoxifen had no inhibitory effect in the presence of 
calphostin C. It was demonstrated previously that calphostin C can reduce MCF-7 
cell viability very potently (66). However, because TRPV6 mediated barium entry 
was also inhibited by tamoxifen, and because barium does not bind to calmodulin 
(217), we conclude that tamoxifen does not inhibit TRPV6 function through 
augmentation of calmodulin-mediated inactivation. Nevertheless, there are several 
other possible sites on TRPV6 predicted to be phosphorylated by PKC. 
Phosphorylation of one or more of these could enhance TRPV6 mediated ion influx.  
 
In summary, we show that tamoxifen inhibits TRPV6 activity via an estrogen receptor 
independent way. This finding may help to explain the mechanism behind the 
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success in therapy of estrogen receptor negative breast tumors with tamoxifen. 
Although the detailed mechanism of how tamoxifen affects TRPV6 still needs to be 
elucidated, we conclude that protein kinase C activity modulates the inhibitory effect 
of tamoxifen. We also found that PKC activation enhances, whereas PKC inhibition 
decreases TRPV6 activity, and that these effects are not mediated by calmodulin. It 
is tempting to suggest that PKC inhibitors used for breast cancer treatment affect 
TRPV6 as well. Our findings suggest that TRPV6 might be a possible target for the 
development of new breast cancer medications.  
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MATERIALS AND METHODS 
 
Materials 
The breast cancer cell lines, MCF-7, MDA-MB-231 and T47D were obtained 
from ATCC, Health Protection Agency and NIH National Cell, respectively. 
Culture Center. Fugene 6 transfection reagent was used from Roche Applied 
Biosystems (Rotkeruz, Switzerland). The EYFP-C1-hTRPV6 vector was a 
generous gift from Prof. Christoph Romanin, Institute for Biophysics, 
Johannes Kepler Universität Linz. 
Rabbit anti-human TRPV6 antibody was obtained from ProteinTech Group Inc. 
(Chicago, IL, USA). Mouse anti-human PMCA antibody was purchased from 
Abcam (Cambridge, UK). Hoechst 33342, goat anti-rabbit IgG conjugated to 
Alexa 594, goat anti-mouse IgG conjugated to Alexa 488, Fura-2 AM, cell 
culture medium RPMI-1640, and cell culture reagents were obtained from 
Invitrogen (Basel, Switzerland). The mounting medium Citifluor AF2 was from 
LucernaChem (Luzern, Switzerland). Tamoxifen citrate was purchased from 
Acros Organics (Geel, Belgium), and ICI 182,780 from Tocris Bioscience 
(Bristol, UK). Phorbol-12-myristate-13-acetate and calphostin C was 
purchased from Calbiochem (Nottingham, UK). All other chemicals were 
obtained from Sigma-Aldrich St Louis, MO, USA). Anti-rabbit IgG HRP 
conjugate (Promega, Madison, WI, U.S.A.), AmershamTM ECLTM Western 
Blotting Detection Reagents (GE Healthcare, Buckinghamshire, UK), 
Complete Mini (protease inhibitors) (Roche Diagnostics GmbH, Mannheim, 
Germany), Immobilon-P Transfer Membrane (Milian, Meyrin, Geneva, 
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Switzerland), and 1% Nonidet P-40 (Roche Diagnostics GmbH, Mannheim, 
Germany) were used for the Western blotting and immunopreciptation. 
 
Cell culture 
The human breast cancer cells lines MCF-7 and T47D were cultured in RPMI-
medium supplemented with 10 % FBS, 1 mM HEPES and 1% 
penicillin/streptomycin. The cells were kept in a cell culture incubator at 5 % 
CO2 at 37 °C and were passaged twice a week.  
 
Real time PCR 
cDNA was prepared for every sample by reverse transcription of total RNA 
isolated with Trizol using TaqMan Reverse Transcription Reagents (Applied 
Biosystems, Foster City, CA) according to the manufacturer’s manual. For all 
experiments mRNA expression was measured by real time PCR using an 
Applied Biosystems 7500 Real Time PCR System. Reactions consisted of 1x 
Mastermix, 0.9 µM forward and reverse primers, and 0.2 µM dual-labeled 
fluorescent probes each for TRPV6 and β-actin. The sequences of the 
forward and reverse primers for TRPV6 were 5′-GGT TCC TGC GGG TGG 
AA-3′ and 5′-CCT GTG CGT AGC GTT GGA T-3′ respectively, with the 
resulting amplicon being 62 bp with a Tm of 60°C. The sequence of the probe 
for TRPV6 was 5′-ACA GGC AAG ATC TCA ACC GGC AGC-3′. The 
sequences of the forward and reverse primers for β-actin were 5′-CCT GGC 
ACC CAG CAC AAT-3′ and 5′-GCC GAT CCA CAC GGA ATA CT-3′ 
respectively, with the resulting amplicon being 69 bp with a Tm of 60°C. The 
sequence of the probe for β-actin was 5′-ATC AAG ATC ATT GCT CCT CCT 
 77
GAG CGC-3′. The specificity of all primers was confirmed by BLAST search. 
Primer Express (Applied Biosystems, Foster City, CA) was used for designing 
primers for TRPV6 and β-actin. All primers were designed to cross exon-exon 
boundaries of the coding sequence. Primers were optimized and validated for 
the comparative Ct method, as described in the manufacturer’s manual. ABI 
Prism SDS software version 1 was used for the analysis of the amplification 
plots. The fold change ± SD in TRPV6 expression was normalized to β-actin. 
 
Immunoprecipitation and Western blotting 
Three confluent 100 mm cell culture dishes of T47D, MDA-MB-231 and MCF-
7 cells were washed 3 times with ice-cold PBS. Cells were lysed in lysis buffer 
(composition: 10 mM Tris-HCl, 150 mM NaCl, 10 mM MgCl, 1% Nonidet P-40, 
and protease inhibitor cocktail) for 30 minutes at 4 oC under constant agitation. 
Samples were centrifuged at 12000 rpm for 20 minutes at 4 oC, and the 
protein concentration of the saved supernatant was adjusted to 2 mg/ml. 
Thereafter, 1 ml of the supernatant was incubated with 4 µg of rabbit anti-
TRPV6 antibody for 1 hour under rotary agitation at 4 oC. The samples were 
then mixed with 30 µl of agarose protein G beads, and the mixture was 
incubated overnight at 4 oC. Beads were washed 3 times with lysis buffer and 
afterwards 40 µl of 2x loading buffer was added. The samples were boiled at 
95 oC for 5 minutes and run on a 6% SDS-PAGE. The samples were 
transferred with a semidry method to a PVDF membrane, and blocked with 
5% milk, 0.5% BSA, and 0.02% sodium azide in PBS overnight at 4 oC. The 
blocked membrane was probed with the same anti-TRPV6 antibody at 1:500 
dilution for 2 hours at room temperature and washed 3 times in PBS with 
 78
0.1% Tween 20 (PBST). An HRP-conjugated, goat anti-rabbit secondary 
antibody (1:20000) was applied for 1 hour at room temperature. After 3 
washes in PBST and one final wash in PBS, enhanced chemiluminescence 
was used to visualize the bands on the membrane. 
 
Immunofluorescence 
3 days before staining MCF-7 and T47D cells (150.000 cells / well) were 
seeded on poly-D-lysine coated cover slips in 6-well plates. All the following 
steps were performed at RT. First, the cells were rinsed twice with TBS and 
then fixed with 4 % PFA in TBS for 15 min. Subsequently, they were washed 
3 times for 10 min with TBS and blocked with TBS supplemented with 10 % 
goat serum for 1 hour. Then, incubation with rabbit anti-TRPV6 (1:100) in TBS 
with 0.5 % BSA and 0.02% NaN3 for 90 min followed by 3 washes with TBS 
for 10 min was performed. The cells were stained with mouse anti-PMCA 
(1:500) for 1h in the same buffer followed by the same washing procedure. 
The cells were incubated first with a goat anti-rabbit secondary antibody 
conjugated to Alexa 594 and then with a goat anti-mouse secondary antibody 
conjugated to Alexa 488 at 1:4000 dilution in TBS with 0.5 % BSA and 0.02% 
NaN3 for 1h separated by 3 10 min washes with TBS. Then, the cells were 
washed 3 times for 10 min and mounted with CityFluor AF2. For staining of 
EYFP-TRPV6 transfected cells Fugene 6 was applied 48hours after seeding 
according to the manufacturer’s manual. After transfection cells were 
incubated for 24 to 48 hours before fixing and mounting the cells as described 
above. 
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Confocal imaging 
The slides were imaged with a confocal, laser scanning microscope setup 
using a Nikon Eclipse TE2000-E fully automatized inverted, epifluorescence 
microscope outfitted with Nikon D-Eclipse C1 laser confocal optics. The 
system equipped with a violet-diode (405 nm) and a multiline Argon (457-
515nm) from Melles Griot, and a Helium/Neon (594 nm) lasers from JDS 
Uniphase. Nikon EZ-C1 3.6 confocal imaging software installed on a HP 
xw4400 workstation was used for image acquisition. Brightness and contrast 
were adjusted with ImageJ.  
 
Ion imaging 
For calcium imaging breast cancer cells (300.000 cells / well) were seeded on 
poly-D-lysine treated coverslips in 35mm-dishes. After 24 hours they were 
transfected with EYFP-TRPV6 plasmid using Fugene 6 according to the 
manufacturer’s manual. After transfection, cells were incubated for 24 to 48 
hours before ionic imaging.  
Cell were loaded with 2.5 µg/ml Fura-2 acetoxy-methyl ester dissolved in 
DMSO containing PluroniC F-1278 20% in serum-free RPMI in cell culture 
incubator for 1 h. Cells were incubated in calcium containing Krebs buffer for 
20 min. For calcium and barium measurement Fura-2 ratios (F340/F380) were 
monitored. All measurements were background corrected. The calcium 
imaging was performed on a Nikon Eclipse Ti-U microscope equipped with a 
Polychrome V+ monochromator (TILL Photonics). A Nikon 40x SFluor 
objective was used for visualization. Images were captured with a 
Hamamatsu Orca-ER monochrome CCD camera. Image acquisition and 
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analysis was performed using Simplepci version 6.2 from CImaging. Basal 
calcium or barium entry was measured as the rate of the increase of Fura-2 
ratio in response to the administration of 1 mM divalent cation into nominally 
calcium free solution. 
 
Statistics 
Data are presented as mean ± SEM. Non-transfected groups were compared 
with Mann-Whitney rank sum test. Spearmans rank correlation test and 
Fisher’s z transformation were used in case of testing significance between 
transfected groups. Differences in the comparison tests lower than p < 0.05 or 
Z0.05 > 1.96 were considered significant. 
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4. Additionally performed experiments and 
preliminary data  
 
 
4.1 Physiological role of TRPV6 in the mammary gland 
 
One other project of my PhD program was to investigate the physiological role 
of TRPV6 in the mammary gland. The goal was to compare the milk calcium 
content and the TRPV6 expression in the mammary gland of normal, early 
lactating and late lactating mice. To address the question of whether TRPV6 
plays a role in the calcium transfer into the milk, I first wanted to determine 
whether there is a difference in milk calcium content between wild-type and 
TRPV6 knock-out mice. I performed experiments were milk, blood and tissue 
for RNA and protein analysis were taken. Then, I tried to isolate primary cells 
from the knockout and wild-type mouse mammary gland to compare calcium 
uptake via calcium imaging. Additionally, I performed cryo-sections and 
immuno-histochemistry with many different TRPV6 antibodies. Unfortunately, 
I failed to find any difference between knock-out mouse and wild-type control 
(figure 5).  
A. 
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B. 
 
Figure 5: staining of mammary gland cryosections of wild-type (A) and knockout mouse (B) 
with Anti-TRPV6 antibody  
 
Our lab also generated polyclonal antibodies against TRPV6, but the results 
using these antibodies were not promising. Also, there was an issue to get 
Western blots working. Even when using ultracentrifugation to isolate 
membrane preparations did not help to detect any specific protein band on 
Western blots. However, we could get a specific band using membrane 
surface biotinylation followed by isolation of labeled proteins  (PinpointTM Cell 
Surface Protein Isolation Kit, Pierce, Rockford, IL, USA) of transiently 
overexpressed TRPV6 in HEK cells (figure 6). Recently, we could 
successfully perform immunoprecipitation of TRPV6 in T47D, MCF-7 and 
MDR-MB-231 cells (data shown in second paper). 
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Figure 6: Western blot with anti-TRPV6 antibody of transiently TRPV6 expressing HEK cells 
after biotinylation compared with co-administration with peptide control  
To move forward with this project, a real specific antibody against TRPV6 that 
works well in tissues would be necessary. Another problem of this project was 
that the knock-out mice compensate their reduced intestinal calcium uptake 
with bone resorption and therefore they have blood calcium levels similar to 
those of wild-type mice. The knock-out mice are also not as fertile as the wild-
type mice which meant that it took very long to obtain lactating knock-out mice. 
Also, because we could not observe any difference in milk calcium content of 
knock-out and wild-type, and because all our knock-out mice strain got a 
pasteurella infection, we finally decided to suspend this project and to focus 
on in vitro experiments to evaluate the role of TRPV6 in breast cancer.  
 
4.2 More findings on the role of TRPV6 in breast 
cancer progression 
 
A) TRPV6 mRNA expression is increased in estrogen receptor- and 
progesterone receptor negative tumor tissue 
 
I recently obtained additional results on the role of TRPV6 in breast cancer 
that might be important for further studies. One of these findings was that 
TRPV6 is not only higher expressed in breast cancer compared to normal 
tissue, but it in PR and ER negative cancer tissue compared to positive tissue 
at the mRNA level (figure 7).  
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Figure 7. Real-time PCR data: delta delta CT values of breast cancer tissue samples 
analyzed on their TRPV6 mRNA content with real-time PCR and grouped into ER+ and ER-
/PR+ and PR-.  
 
 
B) Localization of TRPV6 in T47D breast cancer cells 
 
We also investigated, for the first time, where TRPV6 is exactly localized in 
breast cancer cells. Interestingly, staining of small processes coming out of 
the membranes of T47D breast cancer cells was observed (figure 8).  
 
 
Figure 8: .T47D cells stained with anti-TRPV6 antibody (red) and biotin-steptavidin (green), 
60x 
 
C) TRPV6 seems to be expressed in the plasma membrane 
 
Co-localization studies of TRPV6 and biotin-streptavidin also confirmed that 
TRPV6 is expressed at the plasma membrane of T47D breast cancer cells. Z-
stack was performed to obtain three-dimensional images. In figure 9 it is 
clearly visable that there is co-localization (yellow overlapping). The yello 
arrow show staining of little “processes” that might have a specific function 
and have to be further identified.  
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The biotin-steptavidin staining was used to label the plasma membrane to 
confirm the co-localization. This method has not been published thus far. It 
provides a useful tool for labeling the plasma membrane.  
 
 
Figure 9: Three-dimensional image, Z-stack of confluent T47D cells stained with biotin-
streptavidin (green) and TRPV6 antibody (red) 
 
D) TRPV6 expression in different cell cycle phases in breast cancer cells 
 
I also determined the expression of TRPV6 in different cell cycle phases. To 
this end I applied different treatments to T47D and MCF-7 breast cancer cells 
to enrich them in different cell cycle phases. I used normal serum containing 
medium or serum-free medium to enrich the cells in the G0/G1 phase, and 
nocodazole treatment to increase the number of cells in the G2/M phase. The 
effects of these treatments on the cell cycle are shown in figure 10 (MCF-7 
cells) and Figure 11 (T47D cells).  
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Figure 10 .MCF-7 cells in different cell cycle phases detected with FACS (Dapi staining) after 
treatment with normal serum medium, serum-free medium or nocodazole 
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Figure 11 .T47D cells in different cell cycle phases detected with FACS (Dapi staining) after 
treatment with normal serum medium, serum-free medium and nocodazole 
 
The effect of this on TRPV6 mRNA expression is shown in figure 12. The real-
time PCR data demonstrated that there is no significant change in expression 
of TRPV6 mRNA in MCF-7 cells cpompared to T47D cells. In contrast, the 
expression level of TRPV6 mRNA was significantly lower in T47D cells after 
treatment with nocodazole compared to normal serum and serum-free 
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conditions (the higher the delta delta CT value, the lower is the expression 
level). 
0
2
4
6
8
10
12
serum10% serum-free nocodazole
de
lta
 d
el
ta
 C
T 
va
lu
e 
TR
PV
6 
m
R
N
A
MCF7
T47D
*
de
lta
 d
el
ta
 C
T 
va
lu
e 
TR
PV
6 
m
R
N
A
 
Figure 12: TRPV6 mRNA expression detected using real time PCR in MCF-7 and T47D cells 
after different treatments to enrich them in certain cell cycle phases (*=p<0.05) 
 
With the different treatments that were applied, I could not enrich enough cells 
in the different cell cycle phases and therefore this initial set of results was not 
yet sufficiently reliable. In the future, more experiments should be done and 
the conditions and treatments should be optimized. Of interest would be to 
analyze, using FACS, how MCF-7 cells stably expressing TRPV6 change 
their cell cycle or how a stable knockdown of TRPV6 in T47D cells affects the 
cell cycle phases. 
 
E) Role of TRPV6 in cell adhesion and migration 
 
Another aspect that I wanted to investigate is the function of TRPV6 in breast 
cancer cell adhesion and its implication in cancer cell migration. Therefore, I 
developed a new protocol for a cell adhesion assay and tested a phagokinetic 
migration assay and a transwell assay. Thus far, the experiments were only 
performed with MCF-7 cells and T47D cells and they need to be repeated with 
stably TRPV6 expressing MCF-7 cells to be able to identify TRPV6 mediated 
effects. Initial results of the cell adhesion assay show that MCF-7 cells are 
more dependent on components from the serum for their adhesion (figure 13). 
It appears that T47D cells can adhere better in serum-free medium. 
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Figure:13 . Preliminary results : Adhesion assay with T47D and MCF-7 cells in serum 
containing and serum-free medium 
 
The migration and pharmacokinetic assays still need to be optimized to 
improve the quality of the data. Using these assays, the effect of tamoxifen 
could be further more investigated.  
 
F) Effect of tamoxifen on viability of breast cancer cells 
 
Tamoxifen treatment was additionally investigated using a viability assay in 
MCF-7 and T47D cells. A time and dose response of T47D cell viability after 
tamoxifen treatment (dose response, after 24h) shows that T47D cells are 
more susceptible to tamoxifen compared to MCF-7 cells (figure 14). 
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figure14: Cell viability (XTT assay) of MCF-7 and T47D cells in serumfree (A) and serum 
containing (B) medium treated with different doses of tamoxifen for 24h 
 
For this experimental series, a stable TRPV6 expressing MCF-7 cell line 
would be useful to determine weather tamoxifen is more effective in cells 
expressing high levels of TRPV6.  
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G) Endocytosis in not involved in the effect of tamoxifne on TRPV6 
 
The results of my second paper show that TRPV6-mediated calcium uptake is 
inhibited by tamoxifen. To ensure that this effect is not due to endocytosis, I 
performed membrane biotinylation and selection of the membrane fraction 
with streptavidin beads of MCF-7 cells transiently transfected with an EYPF-
TRPV6 constuct. Subsequently, the Western blot using a GFP-antibody 
showed no difference in the amount of TRPV6-EYPF on the membrane 
(figure 15). The importance of this experiment is ensure that the observed 
inhibitory effect of tamoxifen on TRPV6-mediated calcium influx has nothing 
to do with endocytosis of TRPV6 on the membrane. There is no difference in 
detected protein with or without tamoxifen and therefore, no endocytosis 
involved in this effect. 
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Figure 15: Membrane biotinylation of MCF-7 cells transiently transfected with a TRPV6-EYFP 
construct and treated for 10 min with 10 µM tamoxifen, separation with streptavidin beads and 
Western blot. 
primary.antibody: anti-GFP antibody (ab13970) 1:2000, ON, 4°C;  
sec. antibody: HRP-rabbit anti-chicken/turkey IgG 1:8000, 2h, RT 
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H) Detection of TRPV6 knockdown using ion imaging 
 
Recently in collaboration with Gergely G. Kovaces, I could also succeed in 
finding a model to demonstrate a knock-down of TRPV6 with ionic imaging. 
The KD-value of Fura-2 for cadmium is much lower than for calcium and it is 
known that TRPV6 can transport cadmium as well. Therefore, we tried to use 
cadmium influx to monitor small differences in TRPV6 expression after 
transfecting MCF-7 cells with a TRPV6shRNA-GFP contruct. The obtained 
results show a significant decrease in cadmium influx in the transfected cells. 
Therefore, this assay might be useful to evaluate the effects of the TRPV6 
knockdown in breast cancer cells (figure 16).  
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Figure 16: T47D cells, effect of with a Sure SilencingTM shRNA plamid of TRPV6 (2, Part # 
1019A) (pGeneClipTM hMGFP Vector) from SABiosciences, MD, USA  
 
I) Resveratrol might inhibit TRPV6-mediated calcium uptake 
 
Similar to tamoxifen a study using resveratrol was performed. Resveratrol is a 
plant polyphenol and exhibits a similar structural characteristic as tamoxifen. 
Resveratrol can reduce cell viability in MCF-7 and T47D cells (data not 
shown). Therefore, we tested its inhibitory potential and we could detect that 
resveratrol inhibits TRPV6 mediated Ca2+ uptake in TRPV6 expressing 
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xenopus ooctes dose dependently (figure 17). 
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Figure 17. Resveratrol inhibits TRPV6 calcium transport activity of 45Ca2+ into Xenopus 
oocytes expressing TRPV6. Dilutions of resveratrol were used to inhibit TRPV6 mediated 
calcium uptake into oocytes. Columns, mean; bars, SD; N=6. 
 
The cell viabitlity of T47D and MCF-7 cells after 24h of resveratrol treatment 
with different doses in serum-free medium is shown in figure 18 and figure 19. 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
co
ntr
ol
DM
SO
80
0u
M
40
0u
M
20
0u
M
10
0u
M
50
uM
40
uM
20
uM
10
uM 5u
M
4u
M
2u
M
1u
M
50
0n
M
40
0n
M
10
0n
M
resveratrol concentration
ab
so
pt
io
n 
45
0n
m
 
Figure 18: T47D cell viability (XTT assay) after 24h resveratrol treatment with different doses 
and without serum  
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Figure 19: . MCF-7 cell viability after resveratrol treatment for 24h with different doses without 
serum 
 
It was clearly demonstrated that resveratrol reduces cell viability of T47D and 
MCF-7 breast cancer cells in a dose-dependent manner. For this project, it 
would be interesting to see how potent resveratrol is in inhibiting Ca2+ uptake 
in TRPV6 expressing MCF-7 cells. This would be possible to test using Ca2+ 
imaging. Resveratrol is also known to inhibit PKC function and might be 
therefore a promising compound for conducting studies in regard to previous 
results (218). 
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5. Overall discussion and outlook 
 
This PhD thesis addresses the role of TRPV6 in the pathogenesis of 
adenocarcinomas. The first part of the project focused on the role of TRPV6 in 
breast cancer progression. We started by confirming the upregulation of 
TRPV6 in breast cancer tissues and then demonstrated that TRPV6 is 
important for the proliferation of breast cancer cells in vitro. A knockdown of 
TRPV6 using the siRNA approach led to a significant decrease in cell viability 
in T47D breast cancer cells compared to untreated cells. Calcium and calcium 
influx directly controls life and death decisions in cells. Calcium signaling is 
required for cell proliferation and changes in intracellular calcium levels can 
influence the cell cycle. Therefore, the concentration of calcium is highly 
regulated within the cellular compartments. The G1 phase, the G1/S, and the 
G2/M transition require special calcium signaling pathways, e.g. for the 
expression of immediate-early genes, such as FOS, JUN and MYC (219). In 
this context it is interesting that TRPC6 and TRPV6 have both been shown to 
modulate NFAT-dependent gene transcription in prostate cancer cell lines 
(220;221). It was also found that oncogenes interact with the intracellular 
calcium homeostasis. On the one hand, calcium signaling can be influenced 
by oncogenes. The proto-oncogene Ras can bind to PLCε and activate it and 
subsequently increase the generation of IP3 (222). On the other hand, calcium 
can modulate oncogene signaling. For example, the Ras pathway and the 
ERK1 and ERK2 pathways are affected by calcium (223-225).  
Calcium release from the ER and resulting calcium influx into the 
mitochondria is required for apoptosis (226). In tumor cells, the calcium 
release from the ER can be decreased by BCL2 that inhibits the calcium 
pump SERCA2 (227;228). This might be one mechanism how tumor cells 
increase their chances of survival. If the calcium flux to the mitochondria is 
reduced, apoptosis is probably reduced. Roderick et al. suggests in a review 
article that control of cancer cell proliferation by inhibitors of plasma 
membrane calcium channels has received much attention and remains a 
potential strategy for tumor medication (229).  
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TRPV6 that is expressed at considerably higher levels in cancer tissue 
compared to normal tissue would therefore be a promising therapeutic target 
that could be blocked. No specific TRPV6 inhibitors are known so far, 
although there are numerous reports on the role of TRPV6 in specific cancer 
types. Other known TRP channels that are highly expressed in cancer cells 
are TRPM8 and TRPM1. Their protein expression is changed from normal to 
tumorigenic stage. The TRPC1, TRPC6, TRPM5, and TRPV1 are also 
increased in cancer tissues (230-234). Certainly, some of these channels 
might also be therapeutic targets or diagnostic markers.  
 
Our hypothesis that TRPV6 may serve as s therapeutic target for breast 
cancer is supported by the outcome of the second part of this project. Given 
the chemical structure of tamoxifen, which resembles that of known calcium 
channel blockers, we tested its inhibitory potential on TRPV6 mediated 
calcium influx. Indeed, we demonstrated that tamoxifen citrate inhibits TRPV6 
activity. This effect does not work via the estrogen receptor, but the inhibition 
involves PKC modulation, as demonstrated via activation of PKC which 
reduced the inhibitory effect of tamoxifen. Interestingly, calphostin C, a known 
inhibitor of PKC, had no additive effect on the tamoxifen induced calcium 
influx inhibition and it inhibited calcium influx independent of tamoxifen. 
Treatment of MCF-7 breast tumor cells with calphostin C resulted in cell death 
(235). Calphostin C is a potent inhibitor of PKC that operates through a novel 
mechanism, involving binding to a calcium-induced hydrophobic site on the 
PKC regulatory domain and preventing activation by DAG and phorbol esters 
(236;237). 
Therefore, we conclude that the inhibitory effect of tamoxifen on calcium influx 
via TRPV6 is mediated by PKC. It would also be important to identify the 
amino acid residue where PKC phosphorylates TRPV6 in order to establish 
the link between PKC and TRPV6.  
The exact role of PKC in tamoxifen-induced apoptosis is not clear and there 
are some contradictions as to whether tamoxifen activates or inhibits PKC 
(238). In a partially purified rat brain PKC preparation, tamoxifen inhibits PKC 
activity with an IC50 of 25µM (239). Tamoxifen induces membrane 
translocation and down-regulation of PKC following transient activation and 
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this may be mediated through release of arachidonic acid and generation of 
oxidative stress (240). Since PKC activity is greater in neoplastic breast tissue 
as compared to normal breast tissues, tamoxifen is likely to contribute in vivo 
to the inhibition of proliferation by virtue of its PKC-inhibitory action (241). 
The PKC family comprises 12 serine threonine kinases that are divided into 3 
groups, the classical isozymes (cPKC):α, β1, β2, γ, the novel isozymes 
(nPKC): δ, ε, η, θ and the atypical isozymes (aPKC): ξ, 1/λ. PKC activation in 
general starts with stimulation of tyrosine-kinase receptors and G-protein-
coupled receptors that activate phospholipase C. Activation of phospholipasse 
C increases the plasma membrane level of diacylglycerines and results in re-
localization and activation of PKC isozymes. Next, PKC binds to the plasma 
membrane which induces conformational changes that expose the binding 
sites of the kinase domain and the MEK-ERK (242;243) and PI3K-Akt (244) 
pathways get activated. PKC is involved in cell proliferation, differentiation, 
apoptosis, and angiogenesis and the different PKC isozymes have tissue 
specific roles (245). In vitro studies suggest a positive correlation between 
elevated PKC levels and both the invasive and chemotactic potential of 
human breast cancer cell lines (246). It was shown that PKC-α is over-
expressed in breast cancer (247). Stable transfection of T47D cells with PKC-
α renders T47D human breast cancer cells hormone-independent in vitro and 
in vivo. Also some results in this study suggest that PKC-α over-expression 
may predict resistance to tamoxifen (248). Estrogen receptor positive breast 
cancer cell lines express a considerable amount of PKC-δ, whereas estrogen 
receptor negative breast cancer cell lines express very little PKC-δ (249). 
PKC-δ is likely to play a major role in anti-estrogen resistance in breast 
cancer cells and has been linked with acquired resistance to tamoxifen in 
breast cancer patients (250). Our results demonstrate that tamoxifen has a 
similar effect on TRPV6 mediated calcium uptake and therefore suggest that 
PKC-δ is not involved in this effect. PKC-ε expression and activation have 
been reported to be decreased in malignant breast cancer as compared to 
adjacent normal tissue (251). The different expression levels of PKC-
isozymes make it more challenging to target the right PKC isozyme form in 
breast cancer. One study was designed to investigate the role of the PKC-β 
specific inhibitor LY379196. The study revealed that this inhibitor and found 
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significantly reduced growth of the breast cancer cells MCF-7, MDA-MB-231, 
and BT474 (252). In the future, one could identify the specific isozyme 
responsible for the tamoxifen-induced inhibition of TRPV6. The problem of the 
application of PKC inhibitors in cancer therapy is that there are many isoforms 
of PKC expressed in different tissues with different functions. Therefore, the 
probability of serious side-effects for PKC inhibitors is very high. In summary, 
our data strongly suggest that the mechanism of action of tamoxifen involves 
PKC mediated reduction of calcium influx via TRPV6 in breast cancer cells. 
This could explain the beneficial effect of tamoxifen on estrogen receptor 
negative breast carcinomas. Therefore, TRPV6 could serve as an interesting 
new target for the treatment of certain cancer types that highly express 
TRPV6.  
 
A fellow of our group is also involved in developing specific inhibitors against 
TRPV6. The original series of inhibitors that were designed by Christopher 
Landowski and Matthias Hediger were tested for their ability to block TRPV5 
and TRPV6 mediated calcium uptake using radiotracer uptake studies in 
TRPV6 or TRPV5 expressing Xenopus oocytes. We performed frog surgery to 
get the oocytes, injected cRNA of TRPV6 and TRPV5 into oocytes, and 
performed radioactive uptake studies. A paper with the outcome of this project 
is in preparation:  
Christopher P. Landowski, Katrin A. Bolanz, Yoshiro Suzuki, and Matthias A. 
Hediger. “Chemical inhibitors for the Ca2+ entry channel TRPV6.”  
To validate the potential of TRPV6 as therapeutic target, in vivo experiments 
will need to be performed. The xenograft approach would be useful to test the 
inhibitors in a mouse model. Yet, a better approach would be to use the 
MMTV-neu mice as breast cancer model. These transgenic mice carry a rat 
Erbb2/HER-2/neu oncogene tagged with ovalbumin epitopes OT-I and OT-II, 
which are recognized by T-cell receptors, under the control of the MMTV 
promoter (termed fusion protein neuOT-I/OT-II). In addition, this strain carries 
a mouse Trp53 mini-gene, harboring a G to A point mutation in codon 172 
(changing Arg to His; R172H) driven by the rat whey acidic protein promoter. 
Approximately 85% of compound mutant females develop focal mammary 
tumors at 6-10 months of age. Both virgin and breeder mice develop tumors. 
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Approximately 37% of tumor-bearing mice develop metastatic disease in the 
lung. High expression of neu is detected in tumor tissue while very low levels 
are found in lung and ovary. Female mice carrying only the neuOT-I/OT-II 
mutation develop focal mammary tumors at approximately 18 months of age 
(253). In preliminary studies, we tested paraffin sections of these mice, but we 
could not yet localize TRPV6 successfully with our antibodies (Figure 20).  
 
 
 
Figure 20. Preliminary data: Immunohistochmical staining of a paraffin section of MMTV-neu 
mouse cancer tissue with anti-TRPV6 antibody. 
 
The TRPV6 expression in these mice could be also analyzed using real-time 
quantitative PCR to investigate weather TRPV6 mRNA expression increases 
with increasing tumor stages. The MMTV-neu mice could serve as an 
excellent animal model to investigate the efficiency of TRPV6 inhibitors in vivo. 
Taken together, the results of this PhD-study highlight the potential of TRPV6 
as a therapeutic target for cancer treatment and thus shed light on the 
important role of calcium channels in the pathogenesis of adenocarcinomas in 
general. 
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